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Telomerase is a ribonucleoprotein complex consisting of a reverse transcriptase 
protein unit (TERT) and a RNA unit (TER). Telomerase activity (TA) has been 
observed in ~85% of all human tumors, implying that immortality conferred by 
telomerase, play a key role in malignant transformation (Shay and Bacchetti 
1997). Inhibition of telomerase has been shown to result in telomere-shortening, 
subsequent growth arrest and senescence in a wide range of tumor cell lines 
(Hahn et al. 1999; Zhang et al. 1999). The almost universal presence of 
telomerase in human cancers and cancer stem cells, together with its near-absence 
in most normal tissues make telomerase an attractive therapeutic target. However 
mechanism of telomerase activation in cancer has yet been documented in detail 
and insight into the mechanism will definitely improve telomerase base cancer 
therapy. 
Well-defined signaling pathway (Wnt, EGFR and JAK/STAT) inhibitors that are 
known to play important roles in cancer progression were screened to identify 
new telomerase regulators. Hits from the inhibitors libraries were verified in a 
wide range of cancer cell lines (stomach adenocarcinoma: AGS, breast cancer: 
MCF7, colorectal cancer: HCT116/LS174T) and are therefore expected to be 
general TA inhibitors for some of the major types of cancer. β-catenin/TCF4 
complex was identified as a novel TA regulator from the screen and was later 
found to inhibit TA via transcription regulation of hTERT (human TERT). 




Wnt signaling by inhibiting GSK-3β) treatment as well as overexpression of a 
constitutively active form of β-catenin (Δ-N β-catenin) up regulated hTERT 
mRNA expression and telomerase activity (TA) in cancer cell lines. On the other 
hand, knocking down of endogenous β-catenin via shRNA reduces hTERT mRNA 
expression and TA.  In addition, a β-catenin/TCF4 consensus binding sequence 
from -659bp to -653 bp (5’-TGCAAAG-3’) upstream of transcription start site in 
hTERT promoter was also found and evidences from promoter studies, 
electrophoretic mobility shift assay, and chromatin immunoprecipitation assay, 
showed that β-catenin/TCF4 bind to hTERT promoter in vivo and in vitro. Taken 
together, this is the first study has shown that Wnt signaling regulates telomerase 
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Telomere is the end of a chromosome, it is composed of telomeric DNA and a 
type of protein complex called shelterin. Together, they act as a protective cap on 
the end of chromosomes by protecting it from being degraded by exonucleases 
and prevent end-to-end fusions of chromosomes. Telomere also prevents 
chromosomal end from being recognized as DNA damage and inhibits the 
activation of DNA damage checkpoints. Take together it is essential for general 
genomic stability (de Lange 2009).  
 
1.1.1. Telomeric DNA 
In most eukaryotes, telomeric DNA is made up of a C/A-rich strand and a 
complementary G/T-rich strand. It is a large double stranded DNA duplex 
structure consisting of two telomere loops; telomere DNA folds back on itself to 
form a telomere loop (T-loop) which varies from 25kb to 1Kb in human cells, 
while the single-stranded array of TTAGGG 3' overhang loops back into the 
double strained DNA forming a displacement loop (D-loop) resulting in a stable 3’ 








Figure 1.1. Diagrammatic representation of a T-loop and D-loop structure of a 
telomere. The 3' overhang loops back into the double strained DNA to form a 
stable 3’ end structure. 
 
Telomeric DNA contains species specific tandem repeats that are about six to 
eight nucleotides long; d(TTAGGG)n in humans, d(TTGGGG) in the ciliated 
protozoan and d(TG2-3(TG)1-3) in Saccharomyces cerevisiae (Blackburn 1999; 
Pardue and deBaryshe 1999; Wellinger  and Sen 1997). The length of telomeres 
varies from under fifty base pairs (bp) in some ciliated protozoa, a few hundred 
bp in Saccharomyces cerevisiae and from 5 to 20 Kbp in human depending on 
cell types (de Lange 2005). 
 
1.1.2. Telomeric protein (shelterin) 
In human, telomeric binding protein shelterin is made up of six types of protein 
subunits. Among them are telomeric repeat binding factor 1 (TRF1), TRF2, and 
protection of telomeres 1 (POT1) that recognize and bind directly to the telomeric 
DNA (O'Sullivan and Karlseder 2010). All the three proteins have DNA binding 




octamer complex with high specificity to telomere. The octamer complex consists 
of a TRF1 homodimer, a TRF2 homodimer and a POT1 monomer. Both TRF1 
and TRF2 contain SANT/Myb-type DNA-binding domains that bind 5′-
YTAGGGTTR-3′ in duplex DNA specifically, while POT1 binds specifically to 
single-stranded 5′-(T)TAGGGTTAG-3′ sites both at the 3′ end and at internal 
positions of telomere (Bianchi et al. 1999; Court et al. 2005; Hanaoka et al. 2005; 
Lei et al. 2004; Loayza et al. 2004). Multiples such octamers bind along a stretch 
of telomeric DNA and are interconnected by the other three protein subunits, 
TRF1 interacting protein 1 (TIN2), TINT1/PIP1/PTOP 1 (TPP1), and 
repressor/activator protein 1 (Rap1) (de Lange 2001; O'Sullivan and Karlseder 
2010). The importance of shelterin is evidenced from the conservation of 
shelterin-like complexes across different species of eukaryotes. Nearly all 
eukaryote telomere contain POT1-like proteins, fission yeast and trypanosomes 
have TRF1/2 like protein (Cooper et al. 1998; de Lange 2001; Sfeir et al. 2005) 
while Rap1 is also present in fungi (Chikashige and Hiraoka 2001; Kanoh and 
Ishikawa 2001; Shore 1994). On the other hand, TIN2 and TPP1 by far are only 
present in the telomere of vertebrates (de Lange 2005).  
Shelterin is believed to be involved in the generation and maintenance of 
telomeric structure (T-loop and TTAGGG 3' overhang) and regulation of 
telomerase dependent telomeric synthesis. Shelterin is thought to be required in 
the formation of the T-loop of telomeric DNA (Griffith et al. 1999; Stansel et al. 
2001). T-loops could only be observed under electron microscopy provided that 




proteins that stabilized the DNA structure (Griffith et al. 1999; Stansel et al. 
2001).  In vitro experiments have shown that many components of shelterin have 
DNA remodeling activities. TRF2 was shown to be able to remodel artificial 
telomeric substrates into loops though the process was rather inefficient and may 
infer the requirement of other associating proteins in vivo (de Lange 2005; 
Griffith et al. 1999; Stansel et al. 2001). TRF1 is another shelterin protein that has 
DNA remodeling ability and was shown to be able to loop, bend, and pair 
telomeric repeat arrays. Its ability to modify DNA could be enhanced in the 
presence of TIN2, implying that both proteins have the ability to fold telomeres in 
vivo (Bianchi et al. 1997, 1999; Griffith et al. 1998; Kim et al. 2003). More 
studies looking into the in vitro contribution of the other subunits of shelterin in 
T-loop formation and maintenance as well as the function of shelterin in vivo will 
be needed to provide a better idea on the ability of shelterin in T-loop formation 
and maintenance. In addition, shelterin is also known to be able to affect the 
structure of the TTAGGG 3' overhang of the telomere. Subunits of shelterin were 
shown to be involved in generating and maintaining the 3' overhang. Both POT1 
and TRF2 were shown to be required for the maintenance of telomere structure by 
blocking nucleolytic degradation (Hockemeyer et al. 2005; Lei et al. 2005; Yang 
et al. 2005; Zhu et al. 2003). Inhibition of either POT1 or TRF2 reduced single- 
TTAGGG 3' overhang by up to fifty percent (Hockemeyer et al. 2005; van 
Steensel et al. 1998;).  
Shelterin is also known to protect telomeres from the DNA damage surveillance 




(ATM) and ATM and Rad3-related (ATR) protein kinases though detail 
mechanism has yet being elucidated (d'Adda di Fagagna et al. 2003; Takai et al. 
2003). Telomeres can lose this protection via inhibition of shelterin subunits such 
as TRF2, TIN2, and POT1 or telomere attrition. Data from the over expression 
studies of dominant-negative allele TRF2ΔBΔM and TRF2 knockout mouse 
model provide evidences that loss of function of TRF2 activates ATM kinase 
pathway leading to p53/p21-mediated G1/S arrest (Karlseder et al. 1999; van 
Steensel et al. 1998). Upon the activation of the ATM pathway, DNA damage 
factors such as p53 binding protein 1 (3BP1), γ—histone 2AX (γ-H2AX: a variant 
of histone H2A that localizes to sites of DNA damage), the Meiotic 
recombination 11 (Mre11) complex, Rap1 interacting factor 1 (RIF1) and ATM 
S1981-P (the phosphorylated form of ATM) form telomere dysfunction induced 
foci (TIFs) at the chromosomal ends (Takai et al. 2003). TIFs were also formed 
when TIN2 or POT1 was inhibited (Hockemeyer et al. 2005; Kim et al. 2004). 
Formation of TTIFs was greatly reduced in ATM-deficient cells and caffeine 
(ATM and ATR inhibitor) treated cell, while simultaneous repression of ATM 
and ATR reverse phenotypes of telomere-directed senescence (d'Adda di Fagagna 
et al. 2003). A few possible mechanisms on how shelterin can protect telomeres 
from the DNA damage surveillance and DNA repair pathways have been 
proposed. One of them is based on the recent work done in fission yeast Crb2, 
showing that during DNA damage ATM 53BP1 interact with H3K79me2 of 
histone H3 leading to the activation of DNA damage surveillance and DNA repair 




accessible to 53BP1 in intact chromatin. Therefore inferring form the finding, 
shelterin is believed to play a role in maintenance of T-loop nucleosomal 
organization by concealing chromosome end from the DNA damage surveillance 
pathway. Thus when the telomere is exposed, the last nucleosome might have an 
exposed 53BP1 interaction site thereby activates the DNA damage surveillance 
pathway.  TRF2 was proposed as an ATM inhibitor as it was found to be able to 
physical interacts with ATM at Ser 1981 that is auto phosphorylated and is 
essential for the response to DNA damage (Bakkenist and Kastan 2003; Karlseder 
et al. 2004). In addition, overexpression of TRF2 inhibits S1981 phosphorylation 
and dampens ATM signaling pathway (Karlseder et al. 2004). As shelterin is 
abundant at telomeres but not elsewhere, therefore its ability to constrain ATM 
inhibition is restricted to telomere and will not affect DNA respond damage 
elsewhere in the genome. 
Shelterin is also known to restrict or inhibit telomerase activity at the telomere as 
high level of telomerase alone is insufficient for the extension of telomere, 
telomerase extension of telomere is regulated by shelterin via both non-specific 
steric effects and through specific interactions of telomerase and shelterin 
subunits (Zhao et al. 2011; Counter et al. 1998; van Steensel and de Lange 1997). 
Telomere shortening was observed in TRF1 and TRF2 over expressing cells, 
suggesting that increased packaging of the telomere through possibly by 
promoting formation of T-loop or higher order chromatin structure has made 
telomere less accessible to telomerase (van Steensel and de Lange 1997). On the 




association and lead to telomere elongation (Churikov and Price 2008). Though 
TRF1, TRF2 and POT1 are important in regulating telomerase accessibility to 
telomere, they are not known to interact with telomerase. TPP1 on the other hand 
was shown to bind to telomerase through a specific OB-fold motif and was recruit 
to the telomere and increased the enzyme processivity (Latrick et al. 2010; Abreu 
et al. 2010; Xin et al. 2007). Therefore, shelterin has both inhibitory and 
stimulatory activities within the same complex and is likely to regulate the 
activities in tandem through structural changes during telomere replication. Thus, 
sequestration of DNA terminus by TRF1, TRF2 and POT1 may be relaxed at the 
time when TPP1 recruits telomerase and enhances enzyme processivity. 
The length of telomere is maintained by a dynamic equilibrium between processes 
that shorten and lengthen telomeric DNA. Telomere shortening occurred 
gradually at, approximately 50 nucleotides per cell cycle due to the inability of 
DNA polymerase to completely replicate the genome (Zvereva et al. 2010). 
Chromosome ends that lack sufficient telomeric repeats are prone to 
recombination and fusion that will affect normal cell cycle progression and 
promote genetic instability. Thus, telomeres provide a protective cap for the ends 
of linear chromosomes. In addition, the length of telomere serves as a checkpoint 
for the initiation of cell cycle arrest, which leads to cellular senescence and 
apoptosis. Normal human somatic cells lack telomerase and telomeres decrease 
with each cell division; therefore these cells have a finite capacity for replication. 
On the other hand, stem cells and most cancer cells are able to overcome this 




chromosome 3´end and the complementary strand is completed by DNA 
polymerases. Though telomerase activation is the most commonly used strategy 
to maintain telomere length, some cancer cell lines use the alternative lengthening 
of telomere (ALT) mechanism where the telomere is extended via recombination 




Telomerase, a ribo-nucleoprotein reverse transcriptase, is essential for the 
maintenance of chromosome structure and function. Telomerase is a protein 
complex that contains components such as a catalytic subunit telomerase reverse 
transcriptase (TERT; hTERT for human telomerase reverse transcriptase) and a 
telomerase RNA containing a sequence complementary to the telomeric DNA 
repeat (TER; hTER for human telomerase RNA, mTER for mouse telomerase 
RNA and TLC1 for S. cerevisiae telomerase RNA). TERT is an RNA-dependent 
DNA polymerase with reverse transcriptase activity while TER is the template for 
the addition of telomeric repeats to chromosome termini. In addition, telomerase 
also contains specie specific protein such as X-linked recessive dyskeratosi 
congentia 1 (DKC1) in human (Feng et al. 1995; Morin 1989;). 
In vitro and in vivo evidences in multiple laboratories showed that the holo 
enzyme of telomerase encompasses TERT and TER (Beattie et al. 1998; Collins 
and Gandhi 1998; Vaziri and Benchimol 1998; Weinrich et al. 1997).  Telomerase 




and hTERT (human hTERT) into rabbit reticulocyte lysates.  In vivo telomerase 
activity was reconstructed by ectopic expression of hTERT in telomerase-
negative cells that expresses hTER subunits (Vaziri and Benchimol 1998, Wen et 
al. 1998) or co-expression of hTERT and hTER in Saccharomyces (Bachand et al. 
1999, Bachand et al. 2001).  
 
1.2.1. Telomerase RNA (TER) 
Telomerase RNA (TER) is a member of the snoRNA family; it is an essential 
component of telomerase as it provides the template for addition of telomeric 
repeats to chromosome termini. Most snoRNAs are generated from introns, 
however hTER is an intron-less RNA that is transcribed by RNA polymerase II 
(Feng et al. 1995; Kiss 2002; Zaug et al. 1996). hTER is about 451 nucleotides 
(nt) long but the template for reverse transcription is from nt 46 to 53 from the 
5’end. The rest of the RNA molecular is required for the secondary structure of 
hTER, which is highly conserved among different species of vertebrates (Chen et 
al. 2000). The predicted secondary structure contained four conserved elements; 
pseudoknot domain (CR2/CR3), CR4/CR5 domain, box H/ACA (CR6/CR8) 
domain and CR7 domain. The hTER box H/ACA is only present in higher 
eukaryotes and is essential for hTER accumulation, hTER 3’ processing, and 
telomerase activity in cells (Dez et al. 2001; Dragon et al. 2000; Mitchell et al. 
1999; Mitchell et al. 2000; Pogacic et al. 2000).  All the conserved domains are 
essential for interactions of hTERT with other protein components of telomerase 




therefore are essential for the functional assembly of the telomerase complex (Dez 
et al. 2001; Dragon et al. 2000; Ford et al. 2000 & 2001; Mitchell et al. 1999; Lee 
et al. 2000; Pogacic et al. 2000).  The template region, pseudoknot and CR4–5 
domains are required for telomere binding (Yeo et al. 2005). In addition, hTER 
can also be divided into two regions that interact with hTERT independently; one 
region is between 1 to 209nt (containing telomere template and the pseudoknot 
domain) and the other region is between nucleotides 241 to 330 (containing the 
box H/ACA domain and CR4-CR5 domain) (Mitchell et al. 2000). In vitro 
assembly reactions derived from rabbit reticulocyte lysates and human cell 
extracts with deleted or site-directed hTER mutants also show that; the fragment 
containing 10-159nt from the 5’end is the minimal sequence requirement for 
telomerase activity. In addition, two fragments containing 33-147nt and 146-
325nt from the 5’end cannot produce telomerase activity in the in vitro assembly 
system but when added together can assemble active telomerase (Tesmer et al. 
1999).  Taken together these imply that hTER sequence or the structure involved 
in binding to hTERT and its catalysis are functionally separated (Bachand et al. 
2001; Beattie et al. 1998; Beattie et al. 2001; Valerie et al. 1999). 
 
1.2.2. Telomerase reverse transcriptase (TERT) 
TERT proteins are large, ranging from 103 KDa in S. cerevisiae to 127kDa in 
human and mouse and are highly conserved across species (Greenberg et al. 1998; 




domains (i) telomerase essential N-terminal (TEN) domain, (ii) telomerase RNA 
binding domain  (TRBD domain), (iii) reverse transcriptase domain  (RT domain) 
and (iv) the lowly conserved C-terminal domain (CTE domain) (Jacobs et al. 
2006). The RT domain of hTERT and hTER form the active site of telomerase, 
the TRBD domain links these two components together while the TEN domain 
facilitates the repetitive repeat addition mode of telomerase, which is one of the 
distinguishing features of telomerase, relative to classical reverse transcriptase’s 
(Autexier and Lue 2006; Wyatt et al. 2010). 
 
1.2.3. Dyskerin 
Though the holo enzyme of telomerase encompasses only hTERT and hTER, 
proper telomerase sub-cellular localization and functions require species-specific 
accessory proteins such as dyskerin in human. Dyskerin is a 57kDa nucleolar 
protein encoded by the DKC1 gene at Xq28. Mutation of DKC1 result in X-linked 
dyskeratosis congenita which is an inherited bone marrow failure disorder that is 
usually fatal (Vulliamy et al. 2006). Dyskerin is involved in many cellular 
processes such as ribosome biogenesis, snoRNA maturation, and telomere 
maintenance. It is a pseudouridine synthase and is a subunit of box H/ACA 
ribonucleoprotein particles (RNPs). It is essential for that pseudouridylation of 
snoRNA, which is required for the maturation. DKC1is required for proper 
telomerase activity in vivo through it role in the folding of hTER and maintenance 
of hTER stability (likely through pseudouridylation) as well as being a component 




2005). Evidence from clinical studies show that mutations in DKC1 cause defects 
in telomerase enzymatic activity resulting in the failure to elongate and maintain 
telomere length. Therefore leading to the progressive telomere shortening through 
haploinsufficiency mechanisms, whereby only one copy of wild type DKC1 is 
insufficient to maintain wild type condition, in patients as they age and in 
subsequent generations of offspring (Aubert and Lansdorp. 2008). Therefore 
though hTERT and hTER alone is sufficient for the telomerase activity in vitro, 
DKC1 is still essential for the proper function of telomerase in vivo. 
 
In human, hTERT, hTER and DKC1 are known to be essential for proper 
telomerase function. However, DKC1 and hTER are ubiquitously expressed in all 
cells types, but the expression of hTERT (human TERT) is exclusive to cell with 
telomerase activity and its expression is tightly regulated and absent in most 
somatic cells (Feng et al. 1995; Heiss et al. 1998; Counter et al. 1997; Nakamura 
et al. 1997). The changes in telomerase activity coincide with hTERT mRNA 
expression and independent of hTER expression during cellular differentiation 
(Bestilny et al. 1996; Xu et al. 1999). Collective, the present findings imply that 
the expression of hTERT is the rate-limiting factors in telomerase activation. 
 
1.3. Telomerase in human cancers 
 
One of the most distinctive differences between normal eukaryotic cells and 
cancer cells is that cancer cells have infinite proliferative capacity. There is a fix 




enters senescence and stops dividing (Hayflick and Moorhead 1961; Shay and 
Wright 2000). Early passages of human fibroblasts culture derived from a young 
person have long telomeres whereas old passages have considerably shorter 
telomeres (Lansdorp et al. 1996). Most human somatic cells and stem cells of 
renewal tissues, exhibit progressive telomere shortening throughout life and many 
laboratories have also shown the correlations between telomere shortening and 
proliferative failure of human cells (Counter et al. 1992; Greider 1998, Hayflick 
and Moorhead 1961; Harley et al. 1990; Harley 1991; Lindsey et al. 1991; Shay 
and Wright 2000). Shortening of telomere occurs in every cell division due to the 
end-replication problem associates with semi-conservative DNA replication in 
eukaryotes (Lingner et al. 1995). When telomere shortening in eukaryotes 
eventually makes cell division impossible, it will enter an irreversible growth 
arrest known as replicative senescence. To overcome the division barrier and to 
obtain infinite proliferative capacity, cancer cell has to accumulate enough 
mutations including those that allow them to maintain telomere length stability. 
One of the ways to do so is via reactivation of telomerase or more rarely an 
alternative (ALT) mechanism. Human telomerase reverse transcriptase (hTERT) 
over expressed in telomerase negative normal human cell such as fibroblast, 
retinal pigment epithelial cells and foreskin fibroblasts activated telomerase, 
allowed telomere maintenance and indefinite proliferation. β-galactosidase 
staining (a biomarker for senescence) of such cells was also reduced as compared 
to the control cells (Bodnar et al 1998; Vaziri et al. 1998). In addition, these 




malignancy (Jiang, et al. 1999; Morales et al. 1999). Taken together, telomere 
shortening is an essential contribution to cellular senescence and activation of 
telomerase allows cell to escape senescence in vitro. In normal human cells, 
telomerase is tightly regulated and restricted primarily to germ line cells. In 
addition, it has been observed that there is elevated TA in many cancer cells and 
was found to be correlated with the metastatic property of cancer cells (Shay and 
Bacchetti 1997). In addition, inhibition of telomerase results in telomere-
shortening, subsequent growth arrest and senescence in a wide range of tumor cell 
lines (Hahn et al. 1999; Zhang et al. 1999). In fact, telomerase has been regarded 
as a sensitive biomarker for screening, early cancer detection and prognosis with 
commercially available assays on fresh or frozen tumor biopsies, fluids and 
secretions (Breslow et al. 1997, Holt et al. 1996, Piatyszek et al. 1995, Shay 1998, 
Zhang et al. 2012). 
Mechanism on how cancer cells attend high level of telomerase in cancer is 
largely unknown and two hypotheses have being proposed by Newbold (2002). 
One is the de-repression of hTERT promoter leading to the activation of 
telomerase. Data from chromosome transfer studies show that genes from normal 
human cells could repress telomerase activity in cancer cells through transcription 
repression of hTERT. In consistent with the chromosome transfer studies, 
mutation and epigenetic of these gene are found in many types of cancers.  The 
other hypothesis is; the possibility that human cancers arise from cell with pre 




renewing tissue e.g. the bone marrow, skin (basal layer) and gut (lower crypt) 
(Forsyth et al. 2002).  
Though telomerase is a multi components protein complex, studies have shown 
that only hTERT expression is highly specific to cancer cells and tightly 
associated with telomerase activity, while the other components of telomerase are 
constitutively expressed both in normal and cancer cells (Kanaya et al. 1998; 
Takakura et al. 1998; Kyo et al. 1999). In addition, expression of hTERT has 
been shown to be very specific and sensitive in the diagnosis of malignant 
neoplasms and is over expressed in about ninety percent of malignant tumors 
(Kim et al. 1994). Therefore the key question regarding high level of telomerase 
in cancer cell is whether cancer cells originate from cells that have not robustly 
down-regulated hTERT or whether hTERT-repressed cells undergo hTERT 
derepression. If the former prevails, it implies that the presence of telomerase in 
cancers is a process of ‘selection’ of pre-existing telomerase-positive cells with 
subsequent enhancement of activity such as epigenetic modification that enable 
the maintenance of telomeres indefinitely (Greaves 1996). If the latter prevails, 
telomerase activation is an induction due to genetic or epigenetic inactivating of 
hTERT repressor genes (Shay and Wright, 1996). Though the two hypotheses are 







1.4. hTERT regulation 
The expression of hTERT (human telomerase reverse transcriptase) protein is 
primarily regulated at the transcription level thought it was also know to be 
regulated post-transcriptionally and at points of assembly or localization. 
 
1.4.1. hTERT transcriptional regulation by diverse transcription factors and 
signaling pathways 
The hTERT gene is located on the short arm of chromosome 5 (5p15.33) (Cong et 
al. 1999; Bryce et al. 2000). The hTERT promoter is a TATA-less promoter of 
about 3kb in length and the first 260bp of the promoter which is known as hTERT 
proximal promoter was shown to be sufficient for cancer specific transcription 
activation (Horikawa et al. 1999; Takakura et al. 1999). The promoter contains 
many transcription factors binding sites of which many are found within the 
proximal promoter (Cong et al. 1999; Horikawa et al. 1999; Takakura et al. 1999) 
as shown in Figure 1.2. Some of the transcription factors and co-factors that bind 
on hTERT could be positive regulators that are involved in the transcription 
activation of hTERT or negative regulators that inhibit hTERT transcription 
activation. Some of the known positive regulators are cellular myelocytomatosis 
oncogene (c-Myc), myc-associated factor X (Max), specificity protein 1 (Sp1), 
activating enhancer binding protein-1 and -2 (AP-1 and AP-2), hypoxia-inducible 
factor-1 (HIF-1), E26 transformation specific (Ets) proteins, signal transducer and 




hTERT transcription include mitotic arrest deficient  (Mad) and tumor suppressor 
proteins p53. To date, many of these regulators function in a cell type specific 
manner and the signaling pathways that lead to their specific recruitment were not 
fully elucidated and their exact function in the regulation of hTERT expression are 




Figure 1.2. Representation of transcription factors and their binding sites on 
hTERT promoter.   
 
1.4.1.1. hTERT transcriptional regulation by Myc/Max/Mad network 
Among the multiples DNA binding elements exist on hTERT is two enhancer box 
(E-box: CACGTG) sequences located at –165 and +44. They were regulated by 
the Myc/Max/Mad network. The Myc/Max/Mad network comprises of basic 
helix-loop-helix leucine zipper (bHLHZ) family of transcription factors whose 
distinct interactions result in gene-specific transcriptional activation or repression 
(Grandori et al. 2000). In the hTERT promoter, heterodimers cMyc/Max and 




cMyc/Max leads to the transcription activation while recruitment of Mad1/Max 
lead to repression (Greenberg et al. 1999; Günes et al. 2000; Kyo et al. 2000; Oh 
et al. 2000; Wu et al. 1999). 
Over-expression of c-Myc, recombinant c-Myc in electrophoretic mobility shift 
assay (EMSA) and chromatin immunoprecipitation assay (CHIP) of endogenous 
c-Myc show that c-Myc bind to and activate transcription of hTERT in vitro and 
in vivo (Greenberg et al. 1999; Wu et al. 1999; Xu et al. 2001). Xu et al. (2001) 
showed via chromatin immunoprecipitation assay (CHIP) that endogenous c-Myc 
bind to the E-boxes on the hTERT promoter. In addition, the binding of c-Myc on 
the promoter correlated with the induction of hTERT in proliferating leukemic 
cells implying that c-Myc binds to and activate the transcription of hTERT during 
carcinogenesis (Cong et al. 1999; Greenberg et al. 1999; Kyo et al. 2000; Wang 
et al. 1998; Wu et al. 1999). On the other hand many studies have also disputed 
the claim that c-myc is essential for the transcription regulation of hTERT in 
cancer, as there is a lack of tight correlation in the expression of the two proteins 
in some cancers  (Kirkpatrick et al. 2003; Günes et al. 2000). Therefore it remains 
unclear if c-myc is essential for the transcriptional up regulation of hTERT 
transcription in all cancer type or if it is only essential for a selected group of 
cancer such as leukemia (Kirkpatrick et al. 2003; Günes et al. 2000; Xu et al. 
2001). In the case of Mad1, evidences for the regulation of hTERT promoter by 
the protein come from studies that showed repression of hTERT promoter was 
observed upon overexpression of Mad1 while mutation of E boxes on the 




bind on hTERT promoter in ChIP and in EMSA and the binding was absent when 
E boxes were mutated in EMSA (Lin and Elledge 2003; Oh et al. 2000).  
The regulation of c-Myc and Mad1 on hTERT promoter is complex and depends 
on the timely recruitment of c-Myc and Mad1 on the promoter as well the level 
these proteins in the cell; therefore any signaling pathways that alter either or both 
could potentially affect hTERT transcription. Peroxisome proliferators activated 
receptor (PPARγ) pathway was shown to be able to regulate the Myc/Mad/Max 
network and inhibit hTERT expression in colon cancer cells. 15d-PG J2 and 
rosiglitazone (an endogenous and synthetic PPARγ ligand respectively) were able 
to inhibit hTERT expression and telomerase activity in CaCo-2 colon cancer cells 
(Toaldo et al. 2010). The inhibition is through the down regulation of c-Myc 
expression and c-Myc recruitment to hTERT promoter as well as the up regulation 
of Mad1 expression and Mad1 recruitment to hTERT promoter (Toaldo et al. 
2010). Receptor Ck (a cell-surface receptor specific for the cholesterol moiety in 
lipoprotein particles) dependent signaling is believed to regulate hTERT gene 
transcription contribute via the regulation of PPARγ and c-Myc expression. 
Activated Receptor Ck down-regulate hTERT mRNA expression by down 
regulation the mRNA expression of PPARγ and c-myc (Sikand et al. 2006). In 
addition, using specific activator and inhibitor of protein kinase C (PKC), Sikand 
et al. (2006) showed that the down-regulation of hTERT gene transcription 
involved inhibition of PKC. The epidermal growth factor receptor (EGFR) 
signaling pathway was also shown to regulate hTERT transcription via altering the 




carcinoma HSC-1 cells with AG 1478 (an inhibitor of the epidermal growth factor 
receptor) or with a neutralizing antibody to the epidermal growth factor receptor, 
significantly reduced hTERT mRNA and telomerase activity. These effects were 
result of repression of c-Myc and Sp1 expression and up regulation of Mad1 upon 
treatment (Budiyanto et al. 2003).  
 
1.4.1.2. hTERT transcriptional regulation by Sp1 
GC-boxes (GGGCGG) are binding sites for zinc finger transcription factor Sp1 
and are present in the proximal promoter. At least five GC-boxes are present in 
the proximal promoter as shown in the in vitro binding of SP1 by EMSA 
(Takakura et al. 1999).  SP1 binding of the five GC-boxes are essential for 
transcription activation of hTERT promoter. Over expression of SP1 in human 
cervical cell lines with low endogenous level of SP1 elevated hTERT promoter 
activity in them. In addition, mutation of the GC –boxes reduced promoter 
activity with no promoter activity when all five GC-boxes were mutated (Kyo et 
al. 2000). Thought Sp1 is required for the transcriptional activation of hTERT but 
it is a ubiquitously expressed in non-cancerous cells therefore cannot account for 
the cancer specific transcription of hTERT promoter. The regulation of hTERT 
promoter by Sp1 was shown to involve the EGFR signaling pathway.   Inhibition 
of the pathway via EGFR inhibitor AG 1478 or neutralizing antibody reduced Sp1 
mRNA level and down regulated hTERT expression and telomerase activity 




In addition, the p53 tumor suppression pathway is also known to regulate hTERT 
promoter through interacting with Sp1. p53 is described as "the guardian of the 
genome" and is essential for the maintenance of genomic stability. It mediates 
transcriptional repression via direct interaction with transcription factors or 
components of the transcription machinery such as the TATA binding protein 
(TBP), TATA associated factors (TAFs) and CCAAT-binding factor (CBF). In 
the case of the hTERT promoter, p53 interact with Sp1 (Bargonetti et al. 1997; 
Kanaya et al. 2000; Ko and Prives 1996; Perrem et al. 1995; Xu et al. 2000). 
Overexpression of wild-type p53 down regulates telomerase activity in a number 
of cancer cell lines, independent of its effects on growth arrest and apoptosis, via 
transcription repression of hTERT promoter (Kusumoto et al. 1999; Shats et al. 
2004). hTERT promoter does not contain the classical p53 binding sites nor a 
TATA motif and promoter mapping studies shows that the repression is mediated 
through the Sp1 binding sites (Kanaya et al. 2000). Wild type p53 and Sp1 form a 
complex as shown by co-immunoprecipitation and wild type p53 inhibited Sp1 
binding to its consensus motifs and competed for these binding sites with Sp1 in 
EMSA and in DNase foot printing (Bargonetti et al. 1997; Xu et al. 2000). 
Mutant p53 could not change the Sp1-DNA binding in a EMSA and in DNase 
foot printing (Bargonetti et al. 1997; Xu et al. 2000). Taken together, these imply 
that p53 regulates hTERT expression via binding to Sp1 and renders it 





1.4.1.3. hTERT transcriptional regulation by AP-1 and Ap-2 
Recently, Deng et al (2007) identified AP-2 as a tumor-specific hTERT 
transcription factor in lung cancer. By far, it is the only transcription factor 
identified that can account for cancer specific transcription of hTERT promoter. 
However, it is only studied in lung cancer. More studies are required to determine 
if AP-2 is universally activated in all if not most cancer types. On the other hand, 
AP-1 was identified as a negative transcriptional regulator of hTERT. There are 
two AP-1 binding sites outside the proximal promoter, at –1655 and –718 kb of 
the promoter. Jun D and c-Fos was shown to bind directly on the AP-1 site in 
EMSA and CHIP (Takakura et al. 2005). Over expression of the two proteins in 
luciferase reporter assay reduced hTERT promoter activity while mutations of the 
two binding sites increases the promoter activity (Takakura et al. 2005). Over 
expression of either Jun D or c-Jun was also shown to suppressed hTERT 
transcription. Taken together, the suppression of hTERT via AP-1 sites is due to 
the recruitment of c-Jun, Jun D, and c-Fos (Takakura et al. 2005). Transcriptional 
activation by c-Jun is known to be c-Jun NH2-terminal kinase (JNK) dependent in 
many promoters. The role of JNK in transcriptional suppression by c-Jun is 
unknown. In fact for the hTERT promoter, transcriptional suppression by direct 
binding of c-Jun is shown to be independent of JNK and the exact mechanism that 
leads to AP1 mediated repression of the promoter has not being elucidated 





1.4.1.4. hTERT transcriptional regulation by HIF-1 
hTERT promoter contains two hypoxia response element (HRE: ACGTG) within 
the two E-boxes (CACGTG) at –165 and +44. HRE is the consensus binding 
sequence for hypoxia-inducible factor 1 (HIF-1), a basic helix–loop–helix PAS 
(Period circadian protein, Aryl hydrocarbon receptor nuclear translocator protein, 
Single-minded protein tdoamina) transcription factor. These suggest that 
extracellular signaling through HIF-1 can regulate the expression hTERT. HIF-1 
is a key regulator of oxygen homeostasis and is involved in the regulation of 
many genes involved in angiogenesis and energy metabolism. Hypoxia activated 
the transcription of hTERT mRNA as well as TA and it activated hTERT promoter 
activity in luciferase reporter assay in cervical cancer cells (Nishi et al. 2004, 
Yatabe et al. 2004). The promoter activity of hTERT could be induced at least 2-
fold in luciferase reporter assay by induction of hypoxia  or by over expression of 
the oxygen sensitive HIF-1α subunit of HIF-1 in A2780 ovarian carcinoma cell 
line (Anderson et al. 2006). HIF-1α was also shown to bind to the HIF-1 sites in 
vivo in CHIP assay and the recruitment of HIF-1α to the sites was greatly 
enhanced in hypoxia. HIF-1α siRNA treatment abrogated hypoxia induced hTERT 
mRNA expression and TA. In contrast, Koshiji et al. (2004) showed that HIF-1 
antagonized c-Myc recruitment on hTERT promoter leading to the inhibition 
hTERT expression in colon cancer cells. The difference in the findings could have 
been due to experimental parameters such as different level of oxygen used and 




findings suggest that signaling by hypoxia regulate hTERT gene expression 
through HIF-1, although the mechanisms of action remain to be deciphered. 
 
1.4.1.5. hTERT transcriptional regulation by Ets Proteins 
Ets proteins are a family of mitogen-activated protein kinase (MAPK) dependent 
transcription factors and repressor, all the members of the family have a 85-amino 
acid Ets domain which has high affinity to a core consensus DNA sequence of 
GGAA/T (Myer et al. 2005; Xu et al. 2008). Four Ets binding sites were present 
on the hTERT promoter, two of them are juxtaposed Ets binding site and were 
located between −22bp to −14bp up stream of ATG (figure 1.2) and the other two 
are the EtsA (–243CCTT–246) and EtsB (–96CCTT–99) DNA motifs (Maida et 
al. 2002; Xu et al. 2008).  
Ets1 and Ets2 are members of the Ets family that are known to be highly 
expressed in many human cancers, overexpression of either was shown to 
stimulate cell proliferation, anchorage-independent growth, and tumorigenicity in 
nude mice (Foos and Hauser 2000; Galang et al. 2004; Hahne et al. 2005; Hsu et 
al. 2004; Myers et al. 2005; Seth and Watson 2000). In addition, targeted 
disruption of a single allele of Ets2 gene was shown to limits the growth of breast 
tumors in transgenic mice (Neznanov et al. 1999). Knocking down of Ets2 was 
shown to induce a decrease of hTERT gene expression and an increase in human 
breast cancer cell death that could be rescued by expressing recombinant hTERT. 




phosphorylation upon epidermal growth factor (EGF) activation. EGF activation 
was also shown to up-regulate hTERT mRNA in an MAPK dependent manner and 
the up-regulation was specifically blocked by Mitogen-activated protein kinase 
kinase (MEK) inhibitor (Maida et al. 2002).  The effect of EGF on hTERT has 
also being shown to be dependent on the two juxtaposed Ets binding site located 
between −22 to −14, therefore it was hypothesis that the binding of Ets1/Ets2 on 
two juxtaposed Ets was part of the signaling pathways that lead to EGF activation 
of hTERT. However at present, there are no evidences to show the binding of 
Ets1/Ets2 to the juxtaposed Ets site. On the other hand, in EMSA and ChIP assays, 
Ets2 was shown to bind to the EtsA and EtsB DNA motifs on the hTERT 
promoter in breast cancer cell and the interaction was important for hTERT gene 
expression and proliferation in the cells (Xu et al. 2008). 
In addition, ER81 another member of the Ets family was also found to bind on the 
hTERT gene at two sites outside the promoter region. It was found to bind at the 
end of exon 1 and intron 1 of hTERT (Janknecht 2004). It has been shown that 
oncogenic human epidermal growth factor receptor 2 (HER2), Ras and Raf 
activated MAPK, leading to the activation of ER81 and subsequently up 
regulation of hTERT transcription in telomerase negative cells. Mutation of the 
ER81 binding sites severely suppressed hTERT promoter activity. Blocking of 
signaling from HER2 to ER81 or a dominant- negative ER81 molecule 
suppressed telomerase activity in a HER2 positive breast cancer cell line (Goueli 
and Janknecht 2004). Taken together, these imply that the MAP kinase cascade 




1.4.1.6. hTERT transcriptional regulation by STAT 
Signal transducer and activator of transcription (STAT) proteins are members of a 
family of transcription factors that regulate many aspects of growth, survival and 
differentiation in cells.  They are regulated by sarcoma (Src) and Janus kinase 
(JAK). Upon stimulation by a wide variety of growth factors and cytokines, 
STATs are phosphorylated by Src and Jak family kinases and translocate to the 
nucleus leading to transcription regulation of their target genes (Levy and Darnell 
2002). Of the seven human STAT genes, STAT III and V are known to be 
involved in cancer and in the transcriptional activation of the hTERT promoter 
(Konnikova et al. 2005; Chai et al. 2011). STAT III is constitutively activated in a 
wide variety of human tumors and tumor cell lines. Inhibition of STAT III activity 
in these tumor cell lines typically leads to either growth inhibition or the rapid 
onset of apoptosis (Bromberg 2002). ChIP assay showed that STAT III binds to 
the hTERT promoter region at -3308, -1587 and -1054 up stream of ATG, it 
regulated hTERT expression in both tumor and normal cells (Konnikova et al. 
2005). In addition, hTERT knockdown induces apoptosis in a STAT III dependent 
tumor cell line further suggests that hTERT is an important effector of STAT III 
mediated cell survival (Konnikova et al. 2005). The other member of the STAT 
family that may play a role in the regulation hTERT transcription is STAT V, 
inhibition of STAT V in in BCR-ABL positive CML cell lines by Gleevec leads 
to a reduction of telomerase activity and hTERT mRNA expression as well as 
down regulation of hTERT phosphorylation at tyrosine residues at the 





1.4.1.7. hTERT transcriptional regulation by Estrogen 
 
A part from cancer cells; a small group of normal cells with high proliferative 
activity are also telomerase positive. Endometrial cells for example have 
telomerase activity proportional to estrogen levels during the menstrual cycle, and 
telomerase activity is high during the proliferative phase of the uterine cycle 
(Tanaka et al. 1998; Kyo et al. 2000; Williams et al. 2001). Several experiments 
have also shown that estrogen up-regulates telomerase activity in breast and 
prostate cancer cells (Kyo et al. 1999; Misiti et al. 2000; Nanni et al. 2002; Gao et 
al. 2003). There are two estrogen responsive elements ERE in the hTERT 
promoter, one at –2754 bp and another at –950 bp upstream of ATG.  Tamoxifen, 
an anti-estrogenic agent used in treatment of breast and colon cancer, inhibits 
hTERT promoter activation by estrogen in human ovary epithelium cells (Aldous 
et al. 1999; Gao et al, 2003; Misiti et al. 2000). In addition, Misiti et al. (2000) 
showed that hTERT transcription regulation through ERE (at –950 bp and -2754) 
was c-Myc independent in human ovary epithelium cells. In contrast, Kyo et al. 
(1999) showed that induction of hTERT transcription by estrogen was c-Myc 
dependent in human breast cancer cell MCF7. Though later studies are in 
agreement with regulation of estrogen on hTERT expression, however, it has yet 
to be determined whether this activation is direct or indirectly due to c-Myc up 
regulation by estrogen. Apart from transcription activation of hTERT promoter, 




that lead to the phosphorylation and accumulation of hTERT protein in the 
nucleus. 
 
1.4.2. hTERT transcriptional regulation by epigenetic modification 
 
There are also evidences that suggest hTERT is regulated at the epigenetic level, 
one possibility is through DNA methylation due to the presence of a large CpG 
island in the hTERT promoter. However, a generalized pattern of specific DNA 
methylation correlating with expression of the hTERT has yet been identified. 
Therefore was suggested that this type of regulation may not be a major 
mechanism involved in hTERT expression in cancer (Dessain et al. 2000; 
Devereux et al. 1999). Another form of epigenetic modification is the 
posttranscriptional modifications of histones, which will alter the structure of 
chromatin, as it affects interaction between DNA and nuclear proteins. There are 
five major families of histones in human: H1, H2A, H2B, H3, and H4. Known 
posttranscriptional modifications of histone include methylation, acetylation, 
phosphorylation, ubiquitination, Sumoylation, citrullination, and ADP-
ribosylation. Combinations of such modifications have implication in diverse 
biological processes such as gene regulation, DNA repair, chromosome 
condensation in mitosis and meiosis (Berger  2002; Friedl  et al. 2012; Jenuwein 
and Allis 2001; Jeppesen et al. 1992; Khalil et al. 2004; Kimmins et al. 2005; 
Song et al. 2011; Strahl et al. 2000 Xu et al. 2012). Histone acetylation will lead 




to transcriptional activating complex and RNA polymerase complexes leading to 
the transcription of the promoter. Therefore promoters which have high level of 
acetylated histones are known to be actively transcribed. The level of acetylated 
histone is controlled by two opposing processes; histone acetylation by histone 
acetyltransferase (HAT) and deacetylation by histone deacetylase (HDAC). 
HDAC1 was shown to mediate transcriptional repression via the Sp1 binding sites 
in murine thymidine kinase promoter. hTERT promoter contains multiple Sp1 
sites therefore it is possible that hTERT could be regulated by histone acetylation 
as well (Doetzlhofer et al. 1999). As expected, HDAC inhibitors were shown to 
induce hTERT transcription in telomerase negative cells and the activation 
required intact Sp1 sites in the cells (Cong and Bacchetti 2000; Takakura et al. 
2001). Over expression of dominant negative form of Sp1 abrogates this 
regulation, implying that Sp1 plays an important role in transcriptional repression 
of hTERT through deacetylation (Takakura et al. 2001). Although HDAC 
inhibitors activate hTERT transcription in telomerase negative cells, direct 
evidence showing that histone deacetylation of the hTERT promoter in such cells 
is attenuated during carcinogenesis has yet being documented. 
 
1.4.3. hTERT regulation by alternative splicing 
The hTERT transcript undergoes alternative splicing in many tissues and cell lines, 
hTERT transcript has at least six alternate splicing sites; two deletion sites (known 




1998). One of the deletions (beta site) as well as all the insertions cause premature 
translation terminations while the other deletion (alpha site) lies within a reverse 
transcriptase (RT) motif of hTERT. Splice variants are present during 
development as well as in cancer cell lines (Ulaner et al. 1998). Introduction of 
splicing variants that contained alpha, beta or both deletions failed to reconstitute 
telomerase activity in telomerase-negative cell. In telomerase positive cells, alpha 
variant is a dominant-negative inhibitor of telomerase causing telomere-
shortening leading to cell death (Colgin et al. 2000; Yi et al. 2000). Analysis of 
tumor tissues that are lack of telomerase activity and normal tissue samples show 
that these cells expressing splicing variants (Ulaner et al. 2000). Taken together, 
alternative splicing of hTERT might be one mechanism of telomerase regulation.  
 
1.4.4. hTERT regulation by post-translational modification 
One of the post-translational regulation mechanisms of hTERT is the 
phosphorylation of hTERT protein. hTERT contains two Akt phosphorylation 
sites (220GARRRGGSAS229) and (817AVRIRGKSYV826) and was shown to 
be phosphorylated by Akt  (Kang et al. 1999). In addition, only nuclear and not 
cytoplasmic telomerase activity in human breast cancer cells is inhibited by the 
treatment with protein phosphatase 2A (PP2A) and up regulated by PP2A 
inhibitor okadaic acid (Kang et al. 1999; Li et al. 1998). In CD4+ T-cells, 
stimulation by anti-CD3 lead to the phosphorylation and nuclear translocation of  




Therefore regulation of hTERT phosphorylation might be a mean to regulate its 
nuclear localization and activate it by the movement of the protein from a non-
functional cytosolic location to physiologically relevant nucleus.   
As hTERT is a relatively large protein, Hsp90 chaperone complex (Hsp90, Hsp70 
and p23) is required for the proper folding of nascent hTERT (Lee and Chung 
2010). Hsp90 chaperone complex is also needed for the assembly of active 
telomerase and was shown to be functionally associated with telomerase (Holt et 
al. 1999). Components of the Hsp90 complex is up regulated during malignant 
transformation or in advanced cancers compared to surrounding non-cancerous 
tissues (Akalin et al. 2001). In addition, purified Hsp90 component could increase 
telomerase activity of cell extract with low telomerase activity (Akalin et al. 
2001). Taken together, these suggest that chaperone-mediated regulation of 
telomerase may play a role in telomerase activation in cancer cells. 
 
1.5. Extra-telomeric functions of hTERT 
 
hTERT is a well known essential component of telomerase and is known for its 
ability to lengthen telomere, but it is not the only thing it does in the cell. In recent 
years, many other roles for hTERT in various cellular functions, many of which 
are not fully elucidated yet, have been uncovered (Fu et al. 2000; Zhu et al. 2000).  
hTERT has been shown to be involved in pathways regulating DNA repair, 





1.5.1. hTERT regulates DNA repair 
 
Evidences for a role of hTERT involving in the DNA damage response pathway 
has being accumulating. Work in budding yeast, mouse and human cells shows 
that chromosome breaks at locations distinct from telomeres are occasionally 
repaired by telomere addition which occurs much less frequently than other forms 
of DNA repair (Chan and Blackburn 2002; Flint et al. 1994; Kramer and Haber 
1993; Myung et al. 2001 Sprung et al. 1999; Stellwagen et al. 2003). In addition, 
knocking down of hTERT in human fibroblasts abrogated the cellular response to 
DNA double strand breaks and affected the overall chromatin architecture without 
affecting short-term telomere integrity (Masutomi et al. 2005). Cells lacking 
hTERT also became more radio-sensitivity, with diminished capacity for DNA 
repair, supporting the notion that that loss of hTERT impairs the DNA damage 
response. The effect on DNA repair was shown to be dependent on hTERT 
catalytic activity; hTERT mutants that retain activity but fail to lengthen 
telomeres could rescue the effect in cells under hTERT inhibition (Masutomi et al. 
2005). These evidences implicate that hTERT as a regulator of the DNA damage 
response pathway through its actions on chromatin structure.  
 
1.5.2. hTERT regulates mitochondrial functions under oxidative stress  
hTERT is commonly found in nucleolus or cytoplasm and is recruited to telomere 




outside the nucleus (Bollmann 2008; Maser and DePinho, 2002). hTERT has a 
mitochondrial targeting sequence at its N-terminal. It was exported to the 
mitochondria after release of free radical and mitochondrial extracts was found to 
contain telomerase activity (Haendeler 2003; Santosa et al. 2004). Over 
expression of hTERT in human cell lines shows that mitochondrial telomerase 
increases hydrogen peroxide mediated mitochondrial DNA damage by 
influencing iron metabolism and the effect is dependent on the catalytic activity of 
hTERT (Santosa et al. 2004 and 2006). Santosa et al. (2006) suggested that 
mitochondrial telomerase sensitizes cells to oxidative stress  and has functions 
such as to drive stem cells with high oxidative damage into apoptosis thus 
providing a mechanism to ensuring the quality of the stem cell pool. In contrast to 
these, there is a recent study by Ahmed et al. (2008) that showed overexpressing 
hTERT human fibroblasts cells lower mitochondrial DNA damage, increase 
mitochondrial membrane potential and decrease mitochondrial superoxide 
production and cell peroxide levels therefore improving mitochondrial function. 
This study show that telomerase protects mitochondria under mild stress which is 
a view that is more in line with the other protective, pro-survival functions of 
telomerase in the cell. 
 
1.5.3. hTERT regulates apoptotic pathways 
In mammalian cells, there are two major apoptotic pathways: (1) the 




mitochondria which activates caspase-9, (2) the receptor-mediated pathway which 
involves members of the tumor necrosis factor (TNF) family of death receptors, 
including TNF-related apoptosis-inducing ligand (TRAIL) receptors, which 
activates caspase-8 (Green and Reed, 1998; Ashkenazi and Dixit, 1998). Some of 
the initial evidences that indicate a role of TERT in the apoptosis come from 
studies that show mTERT is involved in regulation of apoptosis in transgenic 
mice and mouse cell culture. Primary neuronal cell cultures  (have high level of 
basal mTERT) and mTERT overexpressing pheochromocytoma cells PC12 were 
protected from trophic factor withdrawal and amyloid peptide induced apoptosis 
by interrupting the cell death process at a point prior to mitochondrial dysfunction 
(Fu et al. 2000; Zhu et al. 2000).  Suppression of TERT level in these primary 
neuronal cell cultures increases their vulnerability to excitotoxins and amyloid 
peptides (Fu et al. 2000; Zhu et al. 2000). Transgenic mice and cardiac myocytes 
expressing TERT reveal a reduced area of myocardial infarction after coronary 
artery ligation and reduced sensitivity to apoptosis respectively (Oh et al. 2001). 
TERT was found to be induced in ischemic cortical areas after occlusion of the 
middle cerebral artery (MCAO) and transgenic mice that overexpress mTERT 
showed significant resistance to ischemic brain injury. hTERT has also been 
shown to be able to install an immortal cell phenotype by preventing apoptosis 
without effecting on genomic stability in cell culture (Brachner  et al. 2006, 
Kondo et al. 1998; Fu et al. 1999, 2000; Kushner et al. 2000). Dominant negative 
form of hTERT when transfected into Hela cells, was able to enhance apoptosis 




apoptosis inducing factor (AIF) from mitochondria. Overexpression of hTERT in 
acute promyelocytic leukemia (APL) cell line was shown to protect it from 
apoptosis induced by the tumor necrosis factor (TNF) or TNF-related apoptosis-
inducing ligand (TRAIL). In addition, down regulation of endogenous hTERT 
protein by RNA interference markedly increased apoptosis induced by both 4625 
(Bcl-2/Bcl-xL bispecific antisense oligonucleotide) and HA14-1 (Bcl-2 inhibitor). 
Overexpression of wild-type and telomerase inactive hTERT mutant blocked Bcl-
2-dependent apoptosis in a p53-independent manner (Bufalo et al. 2005). Down 
regulation of hTERT expression in mammalian breast cancer cell line PMC42 via 
transient expression of hTERT antisense RNA also caused apoptosis that was 
telomere shortening independent. These cells could be rescued by a mutant 
hTERT that does not have telomerase activity (Cao et al. 2002). Apoptosis 
induced by down regulation of hTERT could either be rescued by overexpression 
of p53 or enhanced by knocking down of p53 (Cao et al. 2002). In consistent, 
Rahman et al. (2005) showed that constitutive expression of  either wild type or 
telomerase in active hTERT could increase survival following activation of 
exogenous temperature-sensitive p53 in BL41 Burkitt lymphoma cells and 
inhibited endogenous wild type p53-dependent apoptosis in response to 
mitomycin C in HCT116 colon carcinoma (Rahman et al. 2005).  Taken together, 
these imply that, hTERT can directly inhibit apoptosis by blocking both the 
mitochondrial and the death receptor pathway of apoptosis independent of its 





1.5.4. hTERT regulates cell growth and proliferation  
 
In additional to its ability to regulate apoptosis, hTERT was also found to be 
involved in the regulation of the other fate of life; cell growth and proliferation. 
Ectopic expression of hTERT in human mammary epithelial cells (HMECs) 
results in a promotion of cell growth and diminished requirement for exogenous 
mitogens and inhibition of EGFR reversed these effects (Smith et al. 2003).  One 
of the mechanisms in carcinoma progression is to be able to bypass transforming 
growth factor β (TGF-β) induced arrest growth. It was also shown that TERT 
promoted cell growth by interfering with the TGFβ network of growth factors in 
primary murine cell lines and HMECS (Geserick et al. 2006; Stampfer et al. 
2001). Over expression of hTERT in HMECS, but not catalytically inactive 
hTERT mutant, was capable to confer the TGF-β resistance that has no 
correlation with telomere length of the cells (Stampfer et al. 2001). These 
therefore imply that the ability of hTERT to interfere with the TGF-β network 
was independent of telomere length and required catalytically active hTERT. 
Consistent with the idea that hTERT expression can affect cellular proliferation 
independent of telomere length, overexpression of telomerase in mouse cardiac 
muscle tissue causes both cellular hyperplasia and hypertrophy, and targeted 
expression of mTERT in basal keratinocytes enhanced wound healing and 
elevated rate of carcinogen induced skin cancer at normal telomere length 
(Gonzalez-Suarez et al. 2001). However to date, detail of how hTERT expression 




of the components and interactions of the hTERT and TGF-β signaling pathways 
(Bollmann 2008). 
Apart from the TGF-β signaling pathway, hTERT was also found to be part of the 
Wnt/β-catenin signaling pathway. Initial documentation of a link between β-
catenin and TERT came from studies of the multi-potent stem cells in the hair 
follicle. Expression of stable, active β-catenin causes proliferation of these stem 
cells and initiation of a new phase of hair growth in mouse (Fuchs 2008). 
Telomerase-deficient mice with very short telomeres show impaired hair growth 
due to decreased proliferation and mobilization of multi-potent stem cells in the 
hair follicle. Introduction of mTERT rescued this defect by causing proliferation 
of the quiescent stem cells in the hair follicle that mimics the proliferative and 
hair growth promoting effects of β-catenin (Choi et al. 2008; Sarin et al. 2005). 
mTERT enhanced the expression of genes targeted by β-catenin and was 
independent of mTERT reverse transcriptase activity (Choi et al. 2008; Sarin et al. 
2005).  Subsequently, TERT was found to be required for the expression of Wnt-
regulated genes in several mammalian cells, deletion of TERT reduced expression 
of Wnt target genes which were rescued by the addition of enzymatically inactive 
TERT. Purified hTERT was found to interact directly with Brahma related gene 1 
(BRG1), which is a well know subunit of protein complexes involved in altering 
conformation of chromatin to facilitate transcription, in Hela cells (Park et al. 
2009). mTERT was also found to form complex with BRG1, β-catenin and T-cell 




small intestine. Taken together, these findings imply that TERT as a key 
component of β-catenin transcriptional complex. 
 
1.6. Telomerase related screens  
 
Telomerase is a ribo-nucleoprotein reverse transcriptase with a functional RNA 
component hTER, a catalytic protein subunit hTERT and species-specific protein 
such as DKC1 in human. Telomerase is found in ninety percent of human cancers 
and is essential for the continued proliferation of cancer cells; therefore it is one 
of the most popular anti-cancer targets. Multiple screens have been carried out to 
identify telomerase inhibitors. They vary in form of screening targets as well as 
the screening approaches.  A summary of telomerase targeted cancer therapy and 
screening that has being published is available in table 1.1 and 1.2 respectively. 
Some of the approaches in telomerase cancer therapy are: (1) Antisense 
oligonucleotide against the hTER (telomerase RNA) or hTERT (the catalytic 
subunit) (2) telomerase enzyme inhibitors (3) compounds to inhibit telomerase-
telomere interaction or telomere maintenance (4) compounds to inhibit telomerase 
regulators and (5) telomerase activated immunotherapy.   
Antisense treatment against hTER is one of the approaches that directly inhibit the 
enzyme telomerase. Over the past few years, many pharmaceutical companies 
have conducted massive screening programs for small molecule telomerase 
inhibitors. GRN163L, a N3’→P5’ phosphoramidates (NPS), is an antisense of 
hTER, which has been subjected to clinical trial (Herbert et al. 2005). It forms a 




therefore prevent the assembly if the core enzyme. It was found to be a highly 
potent and specific telomerase inhibitor in many cell types, including breast 
cancer, lung cancer, multiple myeloma and non-Hodgkin’s lymphoma cell lines 
(Dikmen et al. 2005, Gellert et al. 2006, Wang et al. 2004). It was derived from 
the parental compound GRN163, which was a promising hit in Gryaznov et al. 
(2006) oligonucleotides screen. In the screen, oligonucleotides were synthesized 
using phosphoramidite transfer methodology on automated synthesizers and 
telomere repeat amplification protocol (TRAP) was used to assay for oligomers 
that could inhibit telomerase activity (TA). Currently, GRN163L is in Phase I/II 
clinical trials for patients with chronic lymphocytic leukemia and some solid 
tumors such as lung and breast cancer. In fact, GRN163L is the only direct 
inhibitor that went into phase II clinical trials. Antisense oligodeoxynucleotide 
against hTERT has also being investigated. Du et al (2003) showed that Cantide, 
an antisense oligodeoxynucleotide against hTERT that hybridized with the 3′-
untranslated sequences of hTERT mRNA, could down-regulate hTERT mRNA 
levels, decrease telomerase activity and induce caspase-dependent apoptosis in 
hepatocellular carcinoma cells. In addition, Cantide could reduce tumor in mouse 
xenografts model in a dose-dependent manner and prolong survive of the mouse. 
(Yang 2012).  
Another approach that could directly inhibit the telomerase is to inhibit the 
enzyme complex. Small synthetic molecules that can be easily modified and 
optimized is preferred for this approach, such molecules can either bind at the 




search for such inhibits has not been a fruitful task and such drug of telomerase 
has a lag phase between drug administration and clinical response. BIBR1532 was 
one of the few such inhibitors that are effective in inhibiting TA in vitro and in 
mouse xenograft model (Damm et al. 2001). Treatment of human cancer cell lines, 
derived from fibrosarcoma, lung, breast and prostate carcinoma, with BIBR1532 
causes progressive telomere shortening with a proliferation arrest without acute 
cytotoxicity. BIBR1532 treated tumor cells has a much reduced tumorigenic 
potential in a mouse xenograft model and administration of BIBR1532 orally 
daily also inhibited initial tumor growth and resulted in a reduced incidence of 
tumors in mouse. (Damm et al. 2001; Pascolo et al. 2002). BIBR1532 was shown 
to inhibit human telomerase by interfering with the processivity of the enzyme. It 
is a small non-peptide, non-nucleoside and non-competitive inhibitor of human 
telomerase. However BIBR1532 has not progressed into clinical trials due to 
unsatisfactory bioavailability (Pascolo et al. 2002). 
Alternatively, the inhibition of telomerase activity can be done via stabilizing of 
G-quadruplex structure of telomeres with small molecules. These compounds can 
potentially kill tumor cells via two pathways: inhibiting telomerase activity by 
locking the single-stranded telomere substrate into a quadruplex structure, or 
triggering telomere uncapping by generating an abnormal telomere structure. 
Such compounds have shown relatively rapid activity in human tumor xenograft 
studies in mice, with minimal signs of acute toxicity.  However, the presence of 
G-quadruplex in normal cells in our body serves as a threat for non-specific 




As the search for small molecules inhibitors that directly inhibit the enzyme 
telomerase itself has not been a very fruitful task. An alternative approach will be 
to look into compounds that inhibit regulators of telomerase instead. Telomerase 
activity is regulated at many levels: translation modification, transcription 
regulation and even at the signal transduction level. To date, the signaling events 
upstream of the telomerase activation has not being full elucidated. Therefore, 
screens of TA inhibitors focusing on signaling proteins that regulate TA will not 
only be providing new targets for TA related cancer therapy but will also be 
adding valuable information in the aspect of telomerase signaling regulation. 
Cerone et al. (2011) used quantitative TRAP (qTRAP), a real-time polymerase 
chain reaction (PCR) based version of the TRAP assay to conduct a high-
throughput RNAi screening for telomerase regulators. The authors are mainly 
interested in targets that regulate hTER and hTERT transcription. They identified 
a novel target ERK8, which is a rather poorly characterized mitogen-activated 
protein kinase (MAPK). As it is a siRNA base screening, no potential inhibitors 
that can specifically target ERK8 were identified. Bilsland et al. (2009) on the 
other hand, used hTERT luciferase reporter in human ovarian carcinoma A2780 
cells to screen a library with 79 kinase inhibitors and was looking for targets that 
regulate hTERT transcription. hTERT  expression is the rate-limiting factors in 
telomerase activation and its expression is mainly controlled at the transcriptional 
level. Screening for hTERT transcription inhibitors therefore is an appropriate 
approach (Bestilny et al. 1996; Bilsland et al. 1996; Gruber et al. 1999; Heiss et 




inhibitors (Compounds 38; Ro-31-8220/bis indolemaleimide family, Compound 
69; indirubin-39-monoxime/indirubin core and compound 79; kenpaullone/indolo 
benazepinone core) that targeted glycogen synthase kinase 3 (GSK3). GSK3 
inhibitors suppressed hTERT expression, TA and telomere length in several 
cancer cell lines as well as hTERT expression in ovarian cancer xenografts. 
Hence, inhibition of GSK3 signal transduction affects telomerase activation and 
serve as a promising candidate in cancer therapy.  
By far, telomerase active immunotherapy has been the most successful telomerase 
focus cancer therapy with two products going into clinical trial. In telomerase 
active immunotherapy, hTERT peptides were presented as epitopes by the MHC 
and induced immune respond to provide protective immunity against tumors. The 
two products that have advanced to clinical trials are GRNVAC1 and GV1001. 
GRNVAC1 is an autologous product consisting of mature dendritic cells (DC; the 
body's most powerful antigen-presenting cells) that were pulsed with hTERT and 
a portion of a lysosomal targeting signal (LAMP) in vitro and was then returned 
to the patient body. In the body, DC cells was shown to activate cytotoxic T cells 
which will then killed tumor cells that expressed telomerase. As for GV1001, it is 
a TERT peptide p611‑ 626. In phase I/II trials, vaccination with GV1001 caused 
hTERT-specific T-cell responses with minor side effects (Shay and Keith 2008).  
In addition, injection of GV1001 with granulocyte macrophage colony-
stimulating factor (GM-CSF) was shown to be able to cause specific T-cell 
responses in patients with advanced pancreatic and pulmonary cancer (Shay and 




Screening strategy Detail 
 
A siRNA screen targeting on 
kinases and kinases-associated 
genes using qTRAP as readout 
 
The screen uses a siRNAs library 
targeting kinases and kinase-
associated genes. The effects of 
siRNA treatment on TA in Hela 
were accessed using qTRAP. 
Positive control used in the screen 
was siRNAs targeting SRC (v-
SRC sarcoma viral 
oncogene homolog), which is a 
known negative regulator of 
telomerase. Negative control used 
in the screen was siRNAs 
targeting PRKCQ (protein kinase 
C theta) which is a known 
positive regulator of telomerase  
 
To eliminated false positive 
results, cell viability was assessed 
using CellTiterGlo 




Hits obtained can be divided into two groups: (i) mitotic kinases involved in the 
spindle formation and mitotic spindle checkpoint (ii) MAP kinase super-family 




For verification, qTRAP was repeated for the twenty-six hits in Hela, CAL51 
and MCF7 to show inhibition of TA by the hits is not cell type specific. qPCR 
was used to access the effect of the hits on mRNA level of hTERT and hTER 
The hit ERK8 was chosen for further study because it knockdown produces 
significantly reduced TA and the mRNA expression of hTERT and was 









HeLa is used for screening while breast carcinoma cell lines such as  
CAL51, MCF7, MCF10A, and MCF12A are also used for the study. 
 
Limitations The focus is narrow as they were only looking for protein that regulates 
transcription of hTERT and hTER. In addition, the screen could only identify 
novel protein targets but did not identify potential inhibitors for them to work 
on to lead to drug discovery in future. 
 
References High-Throughput RNAi Screening Reveals Novel 








A kinase inhibitory library screen 
that used hTERT luciferase-
reporter system as readout 
 
hTERT  luciferase-reporter was 
transfected into human ovarian 
carcinoma A2780 cells to screen 
for kinases inhibitor (from a 
library of 79 well characterized 



















Six out of the seventy-nine inhibitors were able to inhibit hTERT luciferase 
activity. Out of the six, three are glycogen synthase kinase 3 (GSK3) inhibitors 
and the other three inhibit platelet-derived growth factor receptors (PDGFR) 




GSK3 inhibitors were selected for further studies. The three inhibitors are: 
Compounds 38 (Ro-31-8220, bis indolemaleimide family), 69 (indirubin-39-





The screen identified GSK3 as a potential drug target for cancer therapy. The 
three compounds that inhibited GSK3 was their potential drug targets. 
Cell lines 
used 
A2780 ovarian adenocarcinoma cell is used for screening. Other cell lines used 
in the paper are: 5637 bladder carcinoma, C33A cervical carcinoma, A549 lung 
adenocarcinoma, and HCT116 colon carcinoma cells.  
 
Limitations The scope for the screen is relatively narrow as the group was only looking for 
inhibitors that regulated transcription of hTERT. 
 
References Dynamic Telomerase Gene Suppression via Network 












An intercalating molecules screen 
using radio-label gel base TRAP 
assay as readout 
 
The group was screening for 
compounds that inhibited 
telomerase activity by disrupting 
RNA/DNA duplex formation 
during its catalytic cycle.   
 
Nine intercalating molecules were 
assayed for its ability to inhibit 
TA using the magnetic bead assay 
as reported by Sun et al. (1997). 
This is a radio-label gel base 
TRAP assay in which a 32P-
labeled dGTP is incorporated into 
a telomeric substrate from HeLa 











Of the nine compounds examined, four  (Ethidium bromide, Rivanol, Acridine 




Ethidium is the most potent TA inhibitor obtained from their screen, the group 
move on to optimized this lead compound in another publication (Rangarajan 





Neither ethidium nor its derivatives was ever being shown to be able to kill 
cancer cells in culture or human tumor xenograft studies in animals. 
Cell lines 
used 
Hela cell extract 
Limitations There is a lack of in vivo evidence to show that ethidium or its derivatives can 
kill cancer cells. 






An oligonucleotide screen using 





methodology on automated 
synthesizers and TRAP assay was 
used to detect for oligomers that 
could inhibit telomerase activity. 
Result 
Obtained 
A new form of oligonucleotide : N3’→P5’ phosphoramidates (NPS) was found to be a  




GRN163 was eventually chosen from their collection of phosphoramidates as a drug 
development candidate for cancer via inhibiting telomerase. Lipid modification to the 
parental NPS (GRN163) was carried subsequently and a more potent NPS inhibitor: 
GRN163L was obtained. GRN163L has being shown to be a highly potent telomerase 
inhibitor in many cell types, including breast cancer, lung cancer, multiple myeloma 





Imetelstat (GRN163L) has recently entered into Phase I/II clinical trials in patients 
with chronic lymphocytic leukemia and patients with some solid tumors such as lung 




Human kidney carcinoma Caki-1 cells (JCRB), human epidermal carcinoma A431 
cells (JCRB), human lung carcinoma A549 cells , human prostate carcinoma DU145 
cells  
 
Limitations To date, other than vaccine therapy GRN163L is the most promising drugs for cancer 
via inhibition of telomerase. 
 
References Inhibitors--oligonucleotide phosphoramidates as potential therapeutic agents. 
Gryaznov et al. 2001 
A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer 
Agent. Asai et al. 2003 
 
Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate 






A synthetic small molecules 
screen using TRAP assay as 
readout 
 
A novel class of non-peptide, 
non-nucleoside inhibitors of 
human telomerase was generated. 
The inhibitors were screened in 
Hela cell extract and TRAP was 
used to quantitate TA after 
treatment. 
The effects of the inhibitors on 
DNA and RNA polymerases, 
including HIV reverse 
transcriptase was studied to 





BIBR 1532 was found to be able to inhibit telomerase in Hela extract but not 
DNA and RNA polymerases as well as HIV reverse transcriptase at 
concentrations vastly exceeding its IC50 for telomerase. 
Extended propagation of human tumor cell lines in the presence BIBR 1532 
results in progressive telomere shortening followed by the induction of a 
senescence phenotype and profound anti-proliferative effects in cell cultures 




BIBR153 was shown to be a promising candidate compound in selected model 










Hela cells, HT1080 fibrosarcoma cells, lung cancer cell line NCI-H460, 
fibrosarcoma cell line HT1080, breast cancer cell line MDA-MB231 and 
prostate cancer cell line DU145.  
Immunodeficient nu/nu NMRI mice  
Limitations - 
References A highly selective telomerase inhibitor limiting human cancer cell 
proliferation. Damm et al. 2001 
Mechanism of Human Telomerase Inhibition by BIBR1532, a 








A natural and synthetic 




Fourteen natural and synthetic 
compounds was screen in A549 
cells.  TRAP was used to access 
the effect of the compounds on 
TA of A549. 
Result 
Obtained 
Among the compounds tested, 20-hydroxy-2,3,40,60-




In A549 cells, HTMC inhibited the cell proliferation and decreased the 





HTMC was identified as a new potential therapeutic drug for cancer therapy. 
Cell lines 
used 
A549 human lung adenocarcinoma 
Limitations The mechanism and the target of HTMC are unknown. 
 
References Identification of small molecule inhibitors of telomerase activity through 
transcriptional regulation of hTERT and calcium induction pathway 
in human lung adenocarcinoma A549 cells. Rao et al. 2010 
 
 
Table 1.1.  List of current screening strategies published. A brief summary of the different strategies employed by some laboratories in 









                                                                     Details 
















GRN163L forms stable duplexes with the telomerase RNA (hTER) subunit thus 
prevent it from interacting with the catalytic catalytic subunit (hTERT).  Therefore, 




e of the 
inhibitor 
It is an oligonucleotide therefore probably will not be subjected to common drug-
resistance mechanisms. GRN163L is very specific and binds tightly to hTER.  
 
However, drug target for telomerase has a lag phase between drug administration 
and clinical response. Sustained inhibition is probably required and long treatment 
duration may cause toxicity in some proliferative tissues in patients. 
 
Remarks GRN63L has to be administered intravenously and mode of drug administration is 
inconvenient. Imetelstat (GRN163L) has recently entered into Phase I/II clinical 
trials in patients with chronic lymphocytic leukemia and patients with some solid 
tumors such as lung and breast cancer. 
 
Reference Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate 
























BIBR1532 is a compound that inhibits human telomerase by interfering with the 




e of the 
inhibitor 
Synthetic small molecules can be easily modified and optimized. 
 
However, drug target for telomerase has a lag phase between drug administration 
and clinical response. 
 
Remarks BIBR1532 has not progressed into clinical trials due to unsatisfactory 
bioavailability. 
 
Reference Mechanism of Human Telomerase Inhibition by BIBR1532, a 
Synthetic, Non-nucleoside Drug Candidate. Pascolo et al. 2002 












GV1001 binds multiple HLA class II molecules and harbors putative HLA class I 
epitopes. The peptide is able to elicit combined CD4/CD8 T-cell responses. GV1001 
is injected with GM-CSF (Granulocyte macrophage colony-stimulating factor) to 





e of the 
inhibitor 
No major toxicity observed in all clinical trials (phase I/II) to date. No autoimmunity 
effect was observed after the vaccination.  
Periodical boosting might be required for life-long effects. Immune system of 






Remarks Phase I/II trials in advanced pancreatic and pulmonary cancer patients have demon-
strated that GV1001 produce specific T-cell responses in more than fifty percent of 
subjects, without clinically important toxicity.  
 
However, in a phase III trial by PrimoVax trial, which evaluates GV1001 as mono-
therapy found it to be ineffective. 
 
On the other hand, in the phase II trial by TeloVac, a combination therapy of 
GV1001 with other agents appeared to be promising. 
 
Therefore Identifying the right patient group as well as optimization of dosage and 
frequency of immunizing patients with GV1001 may further improve its clinical 
efficacy. 
 












p540‑ 548  is a hTERT peptide (ILAKFLHWL) which was previously identified by 
investigators from two laboratories (Coulie et al. 1997, Vonderheide et al. 1999) as 
an immunodominant HLA-A*0201-restricted T-cell epitope. The peptide was used 
to induce cytotoxic T lymphocytes (CTL) in vitro. The CTL could recognized cells 
in  breast, colon, lung, melanoma, and prostate cancers that endogenously expressed 





e of the 
inhibitor 
In a clinical trial, Parkhurst et al. (2004) showed that the peptide specific CTL do 
not recognize tumors that endogenously expressed telomerase, and none of the 





Reference Antigens recognized by T-lymphocytes on human tumors. Coulie et al. 1997. 
 
The telomerase catalytic subunit is a widely expressed tumor-associated 
antigen recognized by cytotoxic T lymphocytes. Vonderheide et al. 1999 
Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-
Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously 
Expressing Telomerase Parkhurst et al. 2004  
 
 
TERT 572Y  
 
TERT 572Y is 













The authors believed that cytotoxic T lymphocytes precursors that recognize cryptic 
peptide of hTERT may survive negative selection during development and are 
readily available for activation. They found that tolerance of cryptic peptides was 
weak or absent, and that cryptic peptides could efficiently induced antitumor 





e of the 
inhibitor 
572Y vaccine is well tolerated and effective in eliciting specific TERT(572Y) 
CD8+ . However, the ability of these CD8 clones in destroying tumor cells 
expressing the native TERT peptide has not been studied.  
 
Remarks Long-term data on the development of immune responses are not obtained for the 








Reference A phase I study of the optimized cryptic peptide TERT(572y) in patients with 


















hTERT I540  is derived from the central part of hTERT at the RNA binding region, 
adjacent to the first telomerase reverse transcriptase motif. The peptide hTERT I540 
binds to HLA-A*0201—the most frequently expressed MHC class I allele present in 






e of the 
inhibitor 
Vaccination using hTERT I540 peptide is able to generate detectable hTERT-
specific cytotoxic T lymphocytes in cancer patients. However, it has not been 
established whether or not hTERT I540 induces an immunodominant response. 
Remarks The peptide hTERT I540 binds only to HLA-A*0201, implying that it only activate 
a small subset set of immune cells, therefore its not surprise its does not induce 
immunodominant response. 
 























and a portion 









GRNVAC1 is injected into the patient's skin; from there the dendritic cells travel to 
the lymph nodes and stimulate cytotoxic T-cells to kill tumor cells that express 
telomerase on their surface. 
 
Patients have to undergo leukapheresis to harvest normal peripheral blood 
mononuclear cells for vaccine manufacture. Patient mononuclear cells are 
differentiated in culture to immature dendritic cells, transfected with messenger 
RNA encoding hTERT and LAMP. Transfected dendritic cells are matured and used 





e of the 
inhibitor 
Production of GRNVAC1 is expensive, time consuming and invasive.  
Remarks Vaccination with DC transfected with hTERT mRNA has the potential to generate 
strong immune responses to multiple hTERT epitopes. The addition of the LAMP 
sequence improves the method further. 
 
Reference Telomerase mRNA transfected dendritic cells stimulate antigen-specific CD8+ 
and CD4+ T cell responses in patients with prostate cancer. Su Z et al. 2005 
 
 
Table 1.2.  List of approaches in telomerase cancer therapy. A brief summary of the types of approaches in cancer therapy that target 




1.7. Wnt signaling pathways 
The wingless-int (Wnts) is a large family of highly conserved growth factors, 
which are cysteine rich and consist of about 350-400 amino acids with an N-
terminal signal peptide for secretion. Wnt signaling pathways are important in 
development, cells growth and differentiation (Cardigan and Peifer 2009, Vab 
Amerongen and Nusse 2009; Neel and Muthuswarmy 2012). Wnts ligands can be 
sub-divided into two classes based on their ability to activate β-catenin; The 
classical Wnts (Wnts -1, -3A, -8 and -8B) activate the canonical pathway, 
involving β-catenin as a co-activator. The non-classical Wnts (Wnts -4, -5A and -
11) activate planar cell polarity (PCP) or calcium pathway which are collectively 
know as the non-canonical pathway. Both the canonical and non- canonical Wnt 
pathways are responsible for important developmental events and human diseases 
(Widelitz 2005).   
 
1.7.1. Canonical Wnt pathway 
β-catenin, the key player of the canonical Wnt pathway is encoded by the 
CTNNB1 gene in human and has a homolog called armadillo in drosophila, 
(Kraus et al. 1994). β-catenin consist of about 780 amino acid, can be sub divided 
into three region: (1) The N-terminal region of about 130 amino acids contains 
four consensus phosphorylation sites of glycogen synthase kinase 3 beta (GSK-b), 
upon phosphorylation this region serves as a docking site for E3 ubiquitin ligase 
leading to its degradation, (2) The central region of about 550 amino acids contain 




protein interaction with cadherin, adenomatous polyposis coli tumor suppressor 
protein (APC) and T-cell factor/lymphocyte enhancer factor (TCF/LEF) and  (3) 
C-terminal region of about 100 amino has transactivator function  and is required 
for transcription activation of target genes (Cadigan  and Nusse 1997; Kikuchi et 
al. 2006; Miller and Moon 1996; Morin et al. 1997; Rubinfeld et al. 1997).  
β-catenin is an intracellular signal transducer in the canonical Wnt signaling 
pathway (Noordermeer et al. 1994; Peifer et al. 1991; Peifer et al. 1994). The 
canonical Wnt signaling pathway is regulated at many levels and β-catenin is kept 
very low in the absence of Wnt signals. At the level of receptors, the negative 
regulator Dickkopf (DKK) binds to Lipoprotein Receptor-Related Protein (LRP) 
receptor and inhibit Wnt signaling (Kawano and Kypta 2003) 
In the absence of Wnt signaling, β-catenin level is kept low through the 
interactions between β-catenin and its destruction complex. β-catenin destruction 
complex is made up of GSK-3b, casein kinase (CK1), APC, and axin. Axin is a 
scaffolding protein at the center of the β-catenin destruction complex, it is 
believed to form multimeric polymers through its DIX domain to provide a 
platform for protein-protein interaction holding all components of the destruction 
complex in in close proximity (Luo et al. 2005; Schwarz-Romond et al. 2007). 
Axin itself is further modified by components of the destruction complex; 
Interaction of β-catenin, GSK3 and CK1 with axin lead to the phosphorylation of 
Axin and APC, leading to increase association of Axin and APC with β-catenin 
and enhance β-catenin phosphorylation/degradation (Huang and He 2008; 




and PP2A could inhibit β-catenin phosphorylation/degradation through 
association with Axin. PP1 dephosphorylates Axin and promotes the disassembly 
of the destruction complex whereas PP2A dephosphorylates β-catenin (Luo et al. 
2007, Su et al. 2008). The basal level of axin is extremely low compared to other 
components of the destruction complex in Xenopus oocytes, implying that Axin is 
rate limiting for the complex. Therefore changes in Axin level will not affect the 
availability of the other components of the destruction complex in their non-Wnt 
functions but enabling further insulating of Wnt signaling event (Lee et al. 2003). 
However, there are no evidence showing that the dramatic difference between the 
basal level of Axin and the other components applies across all cell types and 
organisms. In fact, photoreceptor of drosophila photoreceptors has APC being 
extremely low compared to other components and a fifty percent reduction in 
APC levels alters the graded Wingless response (Benchabane et al. 2008). APC is 
a 2843 amino acids protein and is found mutated in over eighty percent of colon 
cancers and mutation of APC leads to the elevation β-catenin level. APC has 
multiple protein-protein interaction domains; it has three SAMP (serine-alanine-
methionine-proline) repeats, which is required for interaction with axin and two β-
catenin binding domains. Interaction between β-catenin and APC was shown to 
prevent PP2A from dephosphorylating β-catenin and promoted β-catenin 
phosphorylation and subsequent degradation (Su et al. 2008). Two members of 
the CK1 family of kinases, CK1 α and CK1ε were known to be involved in Wnt 
signaling pathway.  CK1 α binds Axin and phosphorylates β-catenin at Ser45 




Yanagawa et al. 2002). CK1ε was shown to be able to bind to axin indirectly via 
diversin but the functional effect of the interaction was unknown (Schwarz-
Romond et al. 2002). GSK3 is a serine/threonine protein kinase and has being 
implicated in a diverse array of cellular processes and Wnt signaling pathway is 
just one of them. The C-terminus GSK3 interacts with axin while its active site 
interacts and phosphorylates β-catenin (Dajani et al. 2003). Inhibition of GSK-3-
mediated β-catenin phosphorylation is believed to be the major mechanism 
through which Wnt signals prevent β-catenin degradation. Phosphorylation of β-
catenin by GSK-3 and CK1 eventually lead to its ubiquitination by E3 ubiquitin 
ligase β-TrCP (β-transducin repeat-containing homologue protein) in the SCF 
(Skp1/Cul1/F-box protein)/β-TrCP/FAF1 complex. Poly ubiquitination of β-
catenin eventually leads to its degradation by the 26S proteasome (Zhang et al. 
2012). 
During Wnt signaling, glycoproteins Wnt ligands interact with Frizzled receptors 
and co-receptor LRP causing them to rearrange and leading to the activation of β-
catenin. Upon ligand binding, LRP is phosphorylated by CK1 follows by the 
formation of a complex involving dishevelled (Dvl), axin, and GSK3. These 
prevent GSK3 from phosphorylating β-catenin and leading to the accumulation of 
β-catenin in the cytosol. β-catenin therefore enter the nucleus to interact with 
members of the T-cell factor (TCF)/lymphocyte enhancer factor (LEF) 
transcription factors family. The TCF/LEF family is a group of transcription 
factors, which binds to DNA through their high mobility group domain. In higher 




and TCF-4. All of them bind with high affinity and specificity to the Wnt-
responsive element (WWCAAAG) in transcriptional regulatory regions such as 
promoter and enhancers (Haynes et al. 1996; Giese et al. 1995). They do not have 
transcription activation domain and therefore function as DNA-anchored 
platforms to recruit transcriptional complexes and chromatin remodeling 
complexes (Haynes et al. 1996; Giese et al. 1995; Love et al. 1995; van Houte et 
al. 1993). Loss of function studies and phenotypic rescue experiments in animals 
show the lack of redundancy in function for all the four members. TCF3 mainly 
function as a repressor, LEF1 as an activator, while TCF1 and TCF4 display dual 
transcriptional effects depending on the assays and biological systems used (Gradl 
et al. 2002; Hatzis et al. 2008; Levy et al. 2002; Liu et al. 2005; Nateri et al. 2005; 
Shulewitz et al. 2006; Struewing et al. 2010; Yi et al. 2011). In the absence of 
Wnt signals, TCF/LEF associated with ubiquitous co-repressors such as the 
transducin-like enhancer of Groucho/TLE family members and actively repress 
transcription of Wnt target genes (Cavallo et al. 1998; Levanon et al. 1998; Roose 
et al. 1998). Upon Wnt signals, β-catenin is stabilized and translocated into the 
nucleus to interact with TCF/LEF leading to the displacement of Groucho/TLE. 
Recruitment of transcription activator and chromatin remodeling complexes such 
as Brg1/SWI/SNF and p300/CBP follows, leading to transcription of genes 
associated with cell proliferation (example c-Myc and cyclin D) and apoptosis 






1.7.2. Non-canonical Wnt pathway 
To date, several non-canonical Wnt signaling pathways have been identified, 
among them are: the planar cell polarity (PCP) and Calcium/NFAT pathways. In 
the PCP pathway, Wnt ligands bind to Frizzled leading to the activation of 
Rho/Rac small GTPase and JNK (Jun N-terminal Kinase) via Dsh leading to 
subsequent regulation of cytoskeletal organization and gene expression. The PCP 
pathway plays is important for regulating tissue polarity during gastrulation and 
neural tube formation in the vertebrate embryo (Clark et al. 2009). In the 
Calcium/NFAT pathway, Wnt stimulation activates G-protein and phospholipase 
C (PLC) leading to the rise of intracellular calcium (Saneyoshi et al. 2002). 
Elevation of calcium activate protein kinase C (PKC), Ca2+/calmodulin-
dependent protein kinases II (CaM kinases II) and phosphatase calcineurin, which 
eventually leads to the activation of transcription factors such as nuclear factor of 
activated T-cells (NF-AT) and nuclear factor-kappaB (NF-kB). Calcineurin was 
shown to dephosphorylates members of the NFAT transcriptional factors and this 
facilitates their translocation to the nucleus and subsequent transcriptional 
activation of target genes. In mammals, the NFAT transcription factor family 
consists of five members all of which are calcineurin-regulated (NFATc1, 
NFATc2, NFATc3, and NFATc4) except for NFAT5. Calcineurin/NFAT 
signaling regulates a range of cellular processes and plays essential roles during 
embryonic development of the heart, skull, kidney and brain (Arron et al. 2006; 









2.1.1. Cell lines 
Colorectal cancer cell line HCT116 and LS174T cells were used for screening 
while breast cancer cell line MCF7 and gastric cancer cell line AGS were used for 
verification. MCF7, mammalian breast cell line MCF10A (non-cancerous counter 
part of MCF7), HCT116, human embryonic kidney cell line 293T, human colon 
carcinoma-derived cell lines SW480 and SW620 (SW480 was isolated from the 
primary tumor, while SW620 was from a lymph node metastasis from a patient a 
year apart) were used for mechanism studies. Wnt3a-expressing L-cells were used 
for generating Wnt3a ligands in the form of Wnt-3a conditioned medium and L-
cells (control) were used to generate the control medium for Wnt3a treatment 
assay. 
2.1.2. Inhibitor library 
The InhibitorSelect
TM
 inhibitor library was used for screening for novel 
telomerase activity regulators. It consists of well-defined inhibitors from Wnt, 
EGFR, and JAK/STAT signaling pathway inhibitors libraries purchased from 






 Product Name      Target  
A  
Casein Kinase I Inhibitor, 
D4476  
    CK1  
B  
Casein Kinase II Inhibitor 
III, TBCA   




    Wnt/β-catenin  
D  GSK-3 Inhibitor IX      GSK-3α/β  
E  
PKG Iα Inhibitor, Cell-
Permeable  
    protein kinase G Iα  
F  H-89, Dihydrochloride      protein kinase A  
G  JNK Inhibitor II  
c-Jun N-terminal 
 kinase     (JNK)  
H  K-252a, Nocardiopsis sp.  
CaM kinase II .  
Also  inhibits myosin 
 light chain kinase, 
 protein kinase A , 
 protein kinase C , and 
 protein kinase G  
I  KN-93       CaM kinase II  
J  LY 294002  
     phosphatidylinositol  
     3-kinase inhibitor  
K  
(5Z)-7-Oxozeaenol, 
Curvularia sp.  
     MAPKKK  
     TAK1 activity  
L  PP2  
    Src family of protein 
tyrosine kinases. Inhibits 
p56lck , p59fynT , Hck , 
 and Src .  
M  Rapamycin  
p70 S6 kinase . Prevents 
 the translational 
 activation of IGF-II.  
N  SB 202190      p38 MAP kinase  
O  U0126      MEK1 and MEK2  
 










 Product Name   Target  
A  PD 153035  
potent and specific inhibitor of 
the tyrosine kinase activity of 
the EGFR.  
B  EGFR Inhibitor   
A potent, ATP-competitive, 
and highly selective 
inhibitor of EGFR and 
some EGFR mutants over 
erbB4/Her4 and a panel of 
55 other kinases.  
C  ET-18-OCH3  
A selective inhibitor of 
phosphatidylinositol-
specific phospholipase C  
D  JNK Inhibitor II  
A potent and selective 
inhibitor of c-Jun N-
terminal kinase (JNK)  
E  PD 98059  
Inhibitor of MAP kinase 
kinase that acts by inhibiting 
the activation of MAP kinase 
and subsequent 
phosphorylation of MAP 
kinase substrates.  
F  PD 168393  
Selective inhibitor of EGF 
receptor (EGFR) tyrosine 
kinase activity  
G  AKT Inhibitor VIII  
selective inhibitor of 
Akt1/Akt2 activity  
H  pp2  
A potent and selective 
inhibitor of the src family 
of tyrosine kinases that is  
similar to PP1.  
I  ZM 336372  
Inhibits c-Raf with ten-fold 
increased potency compared 
to B-Raf.  
J  Rapamycin  
Selectively inhibits the 
phosphorylation and 
activation of p70 S6 kinase.  
K  SB 203580  
A specific inhibitor of p38 
MAP kinase that does not 
significantly inhibit the JNK 
and p42 MAP kinase at 100 
µM  
L  AG 490  
Potent inhibitor of epidermal 
growth factor receptor kinase 
auto phosphorylation.  Jak 
family tyrosine  
M  LY 294002  
Specific, reversible PI 3-
Kinase inhibitor that acts on 







Table 2.2. List of EGFR inhibitors examined in the screen.  
 
 Product Name  Target  
A  Indirubin Derivative E804 
Primary target SRC, 
secondary target: Cdk1/cyclin 
E, Cdk2/cyclin A and 
Cdk1/cyclin B. 
B  JAK Inhibitor I 
murine JAK1,     JAK2, 
JAK3 and  Tyk2 
C  JAK2 Inhibitor II JAK2 auto phosphorylation 
D  
SHP 1/2 PTPase Inhibitor, 
NSC-87877 
SHP-1 and SHP-2 protein 
tyrosine phosphatases  
 
Table 2.3. List of JAK/STAT inhibitors examined in the screen.  
 
2.1.3 Plasmids  
Luciferase vectors pGL3-88bp hTERT, pGL3-385bp hTERT and pGL3-949bp  
hTERT , were driven by various length of wild-type hTERT promoter, were kind 
gifts of Prof. Horikawa, Izumi (National Cancer Institute). Three mutants (M1, 
M2 and M3) with mutations in the β-catenin binding site and a wild type hTERT 
(652bp) promoter without the β-catenin binding site were generated (Figure 2.1) 





Figure 2.1. hTERT plasmids that were generated. Three mutants (M1, M2 and M3) 
with mutations in the β-catenin binding site and a wild type hTERT (652bp) 

































2.1.4. List of Primers 
List of primers for qTRAP 
TS  5’ AATCCGTCGAGCAGAGTT 3’ 
ACX  5'-GCGCGGCTTACCCTTACCCTTACC CTAACC-3' 
List of primers for Real-Time PCR 
Human DKC1 5’-CATGAGGTGGTAGCCTGGAT-3’ and 
 5’-ACCACTGTGCCCTGTCTTCT-3’  
Human TER 5’- GCGAAGAGTTGGGCTCTGTC -3’ and 
 5’-CATGTGTGAGCCGAGTCCTG-3’  
Human TERT 5'-ATGCGACAGTTCGTGGCTCA-3' and 
5'-ATCCCCTGGCACTGGACGTA-3'  
Human GAPDH 5'-GTGGACCTGACCTGCCGTCT-3' and     
5'-GGAGGAGTGGGTGTCGCTGT-3'  
List of primers for generating of hTERT plasmids 
M 1 5’- CCGCCT GAG AACCTGCGAAGAGAAATG ACGGGC C-3’ 
and  
 5’- GGCCCGTCATTTCTCTTCGCAGGTTCT CAGGCG G-3’ 
M 2 5’-GCCGCCTGAGAACCTGCAAGAAGAAAT GACGGGCC-3’ 
and  
5’- GGCCCGTCATTTCTTCTTGCAGGTTCTCAG GCGGC-3’   
M 3 5’-GCCGCCTGAGAACCTGCAAGAAGAAAT GACGGGCC-3’ 
and  
5’- GGCCCGTCATTTCTTCTTGCAGGTTCT CAG GCGGC-3’   
PGL3-675 5’-GCGAGATCTGCGAGAAATGACGGGCCT GTGTCAAGG-
3’ and  
5’-GGCCAGGGCTTCCCACGTGCGCAGTAT CCATGGTAT-3’  
List of primers for ChIP 
hTERT 1 5’-CCGGTGGGTGATTAACAGAT-3’ and  
5’-GGACGTGAAGGGGAGGAC-3’  
hTERT 2 5’- CCCCGGTGGGTGATTAACAG -3’ and  
5’- GGAGTGCCTCCCTGCAACAC -3’ 
Sp5 5’- GGGTCTCCAGGCGGCAAG -3’ and 
5’- AGCGAAAGCAAATCCTTTGAATCC-3’ 
gGAPDH 5’- TAC TAG CGG TTT TAC GGG CG-3’ and 
5’- TCG AAC AGG AGG AGC AGA GAG CGA-3’ 
 








2.1.5. List of Antibodies 
 
Antibody name Company and 
Cat. NO. 






ChIP and EMSA 
Normal mouse Ig Santa Cruz; sc-
2025  





Rabbit polyclonal ChIP 
 





































2.2.1. Cell culture 
 
All cells were cultured in an incubator with 5% CO2 and at 37°C. All cells except 
AGS and MCF10A were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Gibco, Invitrogen) with 10% heat inactivated fetal bovine serum (FBS, 
Gibco, Invitrogen) and 1% penicillin-streptomycin mixtures (Gibco, Invitrogen). 
AGS was cultured in Roswell Park Memorial Institute-1640 (RPMI-1640, Sigma-
Aldrich) with 10% FBS and 1% penicillin-streptomycin mixtures. MCF10A was 
cultured in DMEM/F12 with 10% horse serum, 0.02mg/ml of EGF, 0.5µg/ml of 
hydrocortizone, 0.1µg/ml Cholera Toxin, 0.01mg/ml of Insulin and 1% penicillin-
streptomycin mixtures. L-cells (control) and Wnt3a-expressing L-cells (ATCC) 
were cultured in DMEM supplemented with 10% FBS. Wnt3a-expressing L-cells 
were additionally supplemented with 400 μg/ml Geneticin (Sigma-Aldrich). 
All cells were harvested by trypsinization. Growing medium was removed and the 
cells were washed with PBS once. 0.25% (w/v) Trypsin with 0.38 g/L EDTA 
(Gibco, Invitrogen) was added into cell culture dish which was then incubated in 
5% CO2, 37 
o
C for 3minutes (min). Cells were re-suspended with respective 
growth medium and centrifuged at 500 rpm for 5min. The medium was aspirated 
and the pellet was washed twice with PBS. Cells were then collected for 





2.2.2. Wnt-3a treatment 
Wnt3a was added to cell lines in form Wnt-3a conditioned medium from the 
culture of Wnt3a-expressing L-cells. Control medium (CM) for the experiments 
came from the culture medium of L-cells. For the preparation of CM and Wnt-3a 
conditioned medium, cultural medium was collected from cultured parental L-
cells or Wnt3a- expressing L-cells respectively. The medium was filtered and 
diluted to 50% in serum-free DMEM before usage. 
 
2.2.3. Generation of stable cell lines 
Lentiviral pLKO.1 short hairpin RNA (shRNA) against human β-catenin and 
control scramble shRNA lentiviral particles (Sigma) were used to generated 
lentivirus in 293T cells. Retroviral vectors pSUPER-retro containing human β-
catenin sequence and pBabe-hTERT-hygro were used to generate retrovirus in 
phoenix cells. The viruses were used to infect cells and antibiotics selection was 
followed after 24hours (hr) of infection. 2μg/ml puromycin and 100μg/ml 
hygromycin (AG Scientific, Inc.) were used on lentivirus-infected cells and 
retrovirus infected cells respectively for selection. After 14 days of selection, 
stable pools of puromycin or hygromycin- resistant cells were obtained and 






2.2.4. Real-time PCR–based version of telomere repeat amplification 
protocol (qTRAP) 
TA was quantified using qTRAP previously published by Betts et al. (2006) with 
some modification. Respective amounts of cells (1.5 x 10
5
 for MCF7 and AGS 
while 4 x 10
5
 for HCT116 and LS174T cells) per well were seeded in 12-well 
plates. The seeding density was chosen to obtain an optimum 80% confluency 
after 24 hours for drug treatment. Cells were treated with inhibitors or DMSO 
(control) and incubated for 48hr. 3μg of total protein lysate was used for qTRAP 
and the TA was measured. After harvesting, cells were immediately frozen at -
80°C for future analysis or lysed. To extract telomerase, the samples were lysed in 
50μl of 1x lysis buffer and incubated for 30min on ice. Following lysis, the 
samples were centrifuged at 12000x g for 20min at 4°C to remove cell debris. 
Protein concentrations of the lysates were determined using a standard Bradford 
protocol.  Eighty percent (by volume) of the sample was then transferred to a 
fresh micro centrifuge tube and analyzed using qTRAP.  
The telomerase reaction was carried out in 1X TRAP buffer and 50μM each of the 
four dNTPs and 80ng/μl of TS primer (Table 2.4) in a 10μl total volume for 
30min at 30°C and was stopped by incubation at 94°C for 10min. Quantification 
of telomerase reaction was subsequently carried out on the Light Cycler 3.0 
(Roche) by adding 10uL of 2X PCR reaction mixture (2X TRAP buffer, 1mg/μL 
BSA, 4ng/μL ACX primer (Table 2.4), 15% glycerol, 1:20,000 SYBR Green, 
0.08U/μL TAQ polymerase). The PCR conditions used were: 94°C for 10min 




with a standard curve generated, and activity expressed as relative telomerase 
activity relative to the DMSO control. 
 
2.2.5. Telomerase inhibitor screen 
The InhibitorSelect™ inhibitor library, consisted of well defined inhibitors from 
wingless-int (Wnts) inhibitors library (Table 2.1), EGFR (epidermal growth factor 
receptor) inhibitors library (Table 2.2) and the JAK-STAT (Janus Kinase/Signal 
Transducer and Activator of Transcription) inhibitors library (Table 2.3), from 
Calbiochem were used for screening. HCT116 and LS174T were used for the 
screen. Two concentrations per inhibitor were used in the screen. The 
concentration of each inhibitor was chosen based on its half maximal inhibitory 
concentration (IC50). IC50 is a measure of the effectiveness of a compound in 
inhibiting biological or biochemical function. This quantitative measure indicates 
how much of a particular drug or other substance (inhibitor) is needed to inhibit a 
given biological process (or component of a process, i.e. an enzyme, cell, cell 
receptor or microorganism) by half. A low dose of 1x IC50 and a high dose of 5x 
IC50 were used for all inhibitors unless otherwise stated. 
qTRAP was used to quantify the ability of inhibitors in reducing TA, any 
inhibitors  that reduce TA by at least 50% in the screen will be verified in MCF7 






mRNA was extracted using RNeasy kit with on-column DNase digestion (Qiagen) 
according to manufacturer instruction with slight modifications. Cell pellet was 
washed twice with PBS before being lysed by Trizol (Invitrogen). Sample was 
lysed by pipetting up and down for at least six times, followed by centrifugation 
at 12000x g for 10min at 4
o
C. After centrifugation, supernatant was transferred 
into a new 1.5ml micro centrifuge tube. Chloroform was added to the supernatants 
at a 5:1 ratio of trizol to chloroform. The content in the tube was then mixed by 
inversion for 15s before incubation for 2-3min at room temperature. The sample 
was then centrifuged at 12000x g for 15minutes at 4
o
C. After centrifugation, the 
upper colorless layer was transferred into a new 1.5 ml micro centrifuge tube. 1 
volume of 70% ethanol was added to the colorless lysate and mixed by pipetting. 
The sample was transferred to an RNeasy spin column placed in a 2ml collection 
tube and centrifuged for 15seconds (s) at 8000x g. The column was washed with 
350µl Buffer RW1 followed by 15min of DNase I digestion (RNAs free DNASe 
set, Qiagen). After DNAse treatment, the column was washed with 350 µl Buffer 
RW1 once followed by 500µl Buffer RPE twice. After washing, the flow through 
was discarded and the column was centrifuged to dry for 3minutes. RNA was then 
eluted in 40µl RNase-free water. The concentration of mRNA was determined 
using Nanodrop. The mRNA was then stored at -80
o
C till required. Reverse 
transcription was performed using the Promega RT-PCR kit and oligo dT primer 
as per manufacturer's protocol (Promega). Real-time PCR was performed using 




(Qiagen). The primers used for real-time PCR are listed in table 2.4. Data were 
analyzed using the ∆∆CT method. 
 
2.2.7. Western Blot 
Cell pellet was suspended in 50mmol/L Tris-HCl (pH 7.4), 250 mmol/L NaCl, 
5mmol/L EDTA, and 0.1% NP-40 with protease and phosphatase inhibitors (1 
µg/ml Aprotinin, Leupeptin and Pepstatin, 1mM NaF, 1mM Na3VO4 and 1mM 
PMSF). The lysate was centrifuged at 14 000x g for 10min before protein 
quantitation using Bradford assay (Biorad). The lysate was then mixed with 5X 
loading buffer with 20x DTT (Fermentas) and boiled at 95
o
C for 5min. The 
protein was run on SDS-PAGE gel and transferred to nitrocellulose membrane 
(Millipore). After transfer, the membrane was incubated with 5% skimmed milk 
followed by primary antibody and secondary antibody sequentially. Following 
incubation, the membrane was washed using Tris buffered saline- 0.1% (v/v) 
Tween 20 (TBST). Immunostaining was detected with horseradish peroxidase 
(HRP) conjugated secondary antibodies and ECL Plus Detection Reagent (GE 
healthcare).  
 
2.2.8. β-catenin/Tcf4 complex consensus binding sequence 
Putative TCF binding sites (A/T)(A/T)CAAAG in hTERT promoter was identified 
using an in silico tool TFExplorer. TFExplorer is a database for regulatory 




hTERT promoter was obtained from the human genome annotation files provided 
by NCBI.  
 
2.2.9. Generation of mutants   
All wild type hTERT promoters; pGL3-88bp, pGL3-385bp and pGL3-949bp were 
kind gifts of Dr Barrett (National Institutes of Health, Bethesda). The hTERT 
(652bp) promoter was generated using pGL3-promoter (Promega) as the vector 
backbone. It was made by PCR amplification of the wild type pGL3-949bp 
plasmid with PGL3-675 primers (sequence as stated in table 2.4) followed by 
restriction enzyme digestion with Bgl II and Nco and sub-cloning into pGL3-
promoter. Sequencing was followed for confirmation. The other three mutants 
(M1-3) used in the project were generated using site-directed mutagenesis on 
pGL3-949bp, a PCR-based strategy, as stated by the manufacturer 
(QuikChange™ site-directed mutagenesis kit, Stratagene). The mutations were 
confirmed by sequencing.  
 
2.2.10. Luciferase assays 
 
Respective amounts of cells (0.75 x 10
5
 for MCF7, 2 x 10
5
 for HCT116 and 293T 
cells for each well) were seeded in 24-well. After 12hr when cells were adherent, 
co-transfection of 1µg of the reporter constructs and 250ng of renilla luciferase 




48h, cells were washed in PBS and lysed with 65µL of passive lysis buffer 
(Promega). 10µL of lysate per sample was assayed for firefly and Renilla 
luciferase activity, using the dual-luciferase reporter assay system (Promega) in a 
luminescence module (Glomax, Promega). Reporter activity of each sample was 
obtained by normalizing the firefly activity with the Renilla activity. The final 
data read out was presented in form of relative reporter activity that was obtained 
by normalizing reporter activity of the sample with control reporter pcDNA-
K10/12 or pcDNA.  
 
2.2.11. Telomere Length Assay 
DNA was extracted from cells using DNeasy Blood & Tissue Kit (Qiagen). 
Telomere length analysis was carried out using a non-radioactive TeloTAGGG 
Telomere Length Assay (Roche) as described by the manufacturer. Briefly, 1μg of 
DNA per sample was digested with Hinf I/RsaI enzyme mix and separated by gel 
electrophoresis. DNA fragments were transferred to nylon membrane (Amersham, 
GE) and hybridized to telomere specific DIG-labeled prob and was detected by 
DIG-specific antibody conjugated to alkaline phosphatase.  The probe was 
visualized by chemiluminescence detection and subsequent exposure to X-ray 
film (Amersham, GE). Mean telomeric repeat binding factor (TRF) lengths were 







2.2.12. Electrophoretic Mobility Shift Assay (EMSA)  
 
Sense and antisense oligonucleotides containing TCF4 binding sites were labeled 
using Biotin 3’ End DNA Labeling Kit (Thermo Scientific). The binding reactions 
contained 10μg of crude 293T nuclear extract, 1μg of double-stranded 
polydeoxyinosinic-deoxycytidylic acid (poly[dI-dC]-poly[dI-dC]), and 10fmol of 
biotin-labeled probe in 20μl of 1X EMSA buffer (25mM HEPES, pH 7.9, 
62.5mM KCl, 0.05% Nonidet P-40, 2mM MgCl2, 8% Ficoll (400), 500 μg/ml 
bovine serum albumin, 0.5mM PMSF, 5μg/ml each of antipain, leupeptin, 
aprotinin, chymastatin, and pepstatin A and 3.75μl of H2O). The incubation was 
carried out for 30min at room temperature. Unlabeled probes in 500-fold molar 
excess were included at the time of reaction for the competitive binding assays. 
Anti TCF4 and c-Myc antibodies were used for super-shift analysis. 20 μl of the 
reaction was loaded on a 6% non-denaturing polyacrylamide gel and was 
transferred to a nylon membrane. DNA was UV cross-linked to the membrane 
and biotin end-labeled DNA was detected using the streptavidin-horseradish 
peroxidase conjugate and chemiluminescent substrate. 
 
2.2.13. Chromatin Immunoprecipitation (ChIP) assays  
CHIP was performed as stated in the ChIP assay kit (Upstate Biotechnology). 
Briefly, each ChIP assay used 3.3 x 10
6
 of formalin fixed HCT116 cells.  Immune 




with 1ml each of the following buffers: low salt wash buffer (0.1% SDS, 1% 
Nonidet P-40, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, and 150 mM NaCl); high 
salt wash buffer (0.1% SDS, 1% Nonidet P-40, 2 mM EDTA, 20 mm Tris-HCl, 
pH 8.0, and 1500 mM NaCl); LiCl wash buffer (250 mM LiCl, 1% Nonidet P-40, 
1% sodium deoxycholate, 1 mM EDTA, and 10 mM Tris-HCl, pH 8.0) and TE 
(10 mm Tris-HCl, pH 8.0, and 1 mM EDTA) for 10min each. Immune complexes 
were eluted with freshly prepared elution buffer (1% SDS and 0.1 mM NaHCO3). 
Reverse cross-linking was carried out by heating at 65 °C overnight in the 
presence of 0.5M NaCl. DNA was recovered using the QIAquick gel extraction 



























3.1. Inhibitors screening 
 
 
To identify noble telomerase inhibitors from the InhibitorSelect™ inhibitor 
library, consisting of Wnt, EGFR and JAK/STAT inhibitor library, a modified 
qTRAP assay as mentioned in the material and method was used. Telomerase 
activity (TA) was quantified using qTRAP and all data obtained was normalized 
against DMSO as all drugs were reconstituted in it. The concentration of each 
inhibitor was chosen based on its half maximal inhibitory concentration (IC50). 
IC50 is a quantitative measure, which indicates the amount of a particular drug or 
substance (inhibitor) needed to inhibit a given biological process (or component 
of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other 
words, it is the half maximal (50%) inhibitory concentration (IC) of a substance. 
 
Screens and validations were carried out in a wide range of cancer cell lines 
(gastric cancer: AGS, breast cancer: MCF7, colorectal cancer: HCT116 and 
LS174T) that have similar reactivated telomerase but differ in genetic 
backgrounds. Inhibitors that reduced TA by at least 50% in the initial screen using 
HCT116 and LST174T were considered as potent telomerase inhibitors and were 





STAT III and V are known to be involved in the transcriptional activation of the 
hTERT promoter (Konnikova et al. 2005; Chai et al. 2011), thus their respective 
inhibitors served as positive controls for our screening platform.  
 
3.1.1. Verification of screening platform using STAT III and IV inhibitors  
 
As shown in figure 3.1, STAT III and V inhibitors were able to reduce TA in 











Figure 3.1. STAT III and V inhibitors were able to reduce TA in HCT116 cells by 

















3.1.2.Wnt pathway inhibitor library screening 
 
Fifteen well-defined Wnt pathway inhibitors, as listed in table 2.1, were used for 
the screen. A low dose of 1x IC50 (Figure 3.2A & Figure 3.3A) and a high dose of 
5x IC50 (Figure 3.2B & Figure 3.3B) were used in the experiments with the 
exception of inhibitor C. Inhibitor that could reduce TA by 50%, in either 
HCT116 (Figure 3.2) or LS174T (Figure 3.3) was considered as positive hit.  The 
amount of inhibitor C supplied as part of the library can only achieve a maximum 
of 2.5x IC50; despite the lower concentration it was able to significantly reduce 
TA in the screen.  
 
Inhibitors C (FH535: β-Catenin/Tcf inhibitor) and F (H-89, dihydrochloride: 
protein kinase A) reduced TA in HCT116 by more than 50% at both 1x and 5x 
IC50 (2.5x IC50 for C). Inhibitors B (TBCA:  casein kinase II inhibitor III) and K 
((5Z)-7-Oxozeaenol; MAPKKK inhibitor) could reduce TA in HCT116 by more 
than 50% at 5x IC50. Only inhibitor C was able to reduce TA in LS174T by more 











Figure 3.2. Effect of TA by Wnt pathway inhibitors compounds A to O in 
HCT116 at (A) 1x IC50 and  (B) 5x IC50 (except inhibitor C that was at 2.5x IC50). 
Inhibitors C and F reduced TA in HCT116 by more than 50% at both 1x and 5x 
IC50 (2.5x IC50 for C). Inhibitors B and K could only reduce TA in HCT116 by 





HCT116 (Drugs at 1x IC50) 








Figure 3.3. Effect of TA by Wnt pathway inhibitors compounds A to O in 
LS174T at (A) 1x IC50 and  (B) 5x IC50 (except inhibitor C that was at 2.5x IC50). 
Only inhibitor C at 2.5x IC50 was able to reduce TA in LS174T by more than 50%. 





LS174T (Drugs at 1x IC50) 




 Product Name  Target  
HCT116 
B  
Casein Kinase II Inhibitor 






F  H-89, Dihydrochloride  protein kinase A  







Table 3.1. A summary of positive hits from Wnt pathway inhibitor library 
screening in HCT116 and LS174T. Inhibitors C and F reduced TA in HCT116 by 
more than 50% at both 1x and 5x IC50 (2.5x IC50 for C).  Inhibitors B and K could 
only reduce TA in HCT116 by more than 50% at 5x IC50. Only inhibitor C was 
able to reduce TA in 293T by more than 50%, therefore inhibitor C was the most 


















3.1.3. EGFR pathway inhibitor library screening 
 
Thirteen well-defined EGFR pathway inhibitors as listed in table 2.2 were used 
for the screen. A low dose of 1x IC50 and a high dose of 5x IC50 were used in the 
experiments. Inhibitors that could reduce TA by 50%, in either HCT116 (Figure 
3.4) or LS174T (Figure 3.5) were considered as positive hits.  
 
Inhibitor C (ET-18-OCH3; phosphatidylinositol-specific phospholipase C 
inhibitor), G (AKT Inhibitor VIII) and M (LY 294002: PI 3-kinase inhibitor) were 
able to inhibit TA in HCT116 (Figure 3.4B) by more than 50% at 5x IC50. 
Inhibitor B (inhibitor of EGFR receptor), C and M inhibited TA in LS174T 
(Figure 3.5B) by more than 50% at 5x IC50. Only inhibitor C and M were able to 
inhibit TA in both HCT116 and LS174T. Inhibitor G was the strongest inhibitor 
of TA in HCT116 but could not reduce TA in LS174T. Inhibitor B on the other 













Figure 3.4. Effect of TA by EGFR pathway inhibitors compounds A to M in 
HCT116 at (A) 1x IC50 and (B) 5x IC50. Inhibitor C, G and M reduced TA in 










HCT116 (Drugs at 1x IC50) 









Figure 3.5. Effect of TA by EGFR pathway inhibitors compounds A to M in 
LS174T at (A) 1x IC50 and (B) 5x IC50. Inhibitor B, C and M reduced TA in 









LS174T (Drugs at 1x IC50) 




 Product Name  Target  
HCT116 
C  ET-18-OCH3  
Phosphatidylinositol-
specific phospholipase C 
G AKT Inhibitor VIII 
A serine/threonine protein 
kinase 
M  LY 294002  
Specific, reversible PI 3-
Kinase inhibitor that acts 
on the ATP-binding site of 
the enzyme. 
LS174T 
B  EGFR Inhibitor 
A potent, ATP-competitive, 
and highly selective 
inhibitor of EGFR and 
some EGFR mutants over 
erbB4/Her4 and a panel of 
55 other kinases.  
C  ET-18-OCH3  
A selective inhibitor of 
phosphatidylinositol-
specific phospholipase C  
M  LY 294002  
Specific, reversible PI 3-
Kinase inhibitor that acts 
on the ATP-binding site of 
the enzyme..  
 
Table 3.2. A list of positive hits from the EGFR pathway inhibitors library screen. 
Inhibitors C and M were able to reduce TA in both HCT116 and LS174T by more 
than 50% in the screens. Inhibitor G was the strongest inhibitor of TA in HCT116 
but could not reduce TA in LS174T. Inhibitor B on the other hand could reduce 




















3.1.4. JAK/STAT pathway inhibitor library screening 
 
Four well-defined JAK/STAT pathway inhibitors, inhibitor A (E804: Sarcoma 
(SRC) inhibitor), B (JAK Inhibitor I), C (JAK2 Inhibitor II) and D (NSC-87877: 
SHP 1/2 PTPase Inhibitor) listed in table 2.3 were used for the screen. A low dose 
of 1x IC50 and a high dose of 5x IC50 were used in the experiments. None of the 
inhibitors could reduce TA in HCT116, therefore were not tested in LS174T nor 














Figure 3.6. Effect of TA by JAK/STAT pathway inhibitors A to D in HTC116 at 

















3.2.  Validation of the positive hits from the screening experiments in MCF7 
and AGS 
 
3.2.1. Verification for Wnt inhibitors 
 
Inhibitor B (TBCA:  casein kinase II inhibitor III), C (FH535: β-Catenin/Tcf 
inhibitor), F (H-89, dihydrochloride: protein kinase A) and K ((5Z)-7-Oxozeaenol; 
MAPKKK inhibitor) from the Wnt pathway inhibitor library were used to treat 
MCF7 (breast cancer cell line) at a dose of 5x IC50 (except inhibitor C that was at 
2.5x IC50). As shown in figure 3.7A, only inhibitor C (FH535) could reduce TA 
by 50% in MCF7. The reduction of TA in MCF7 was concentration dependent as 
shown in figure3.7B and a minimum 2.5x IC50 of FH535 was needed to reduce 
TA in MCF7 by at least 50%. 
FH535 was also able to reduce TA in AGS (gastric cancer cell line) at 2.5x IC50 
as shown in figure 3.8. Implying that FH535 is a cell type independent TA 
inhibitor as it can inhibit TA in a wide range of cancer cell lines (gastric cancer: 
AGS, breast cancer: MCF7, colorectal cancer: HCT116 and LS174T). FH535 is a 
small molecule that interferes with β-catenin/TCF complex interaction and is 
known to inhibit transcription activation of many canonical Wnt regulated gene 
(Tanaka et al 2011). Therefore β-catenin was a potential novel regulator for TA 











Figure 3.7. (A) Effect of TA by Wnt pathway inhibitors compounds B, C, F and K 
on MCF7 at a dose of 5x IC50 (2.5x IC50 for C). (B) Concentration dependent 
effect of inhibitor C (FH535) on MCF7. Only inhibitor C (FH535) was able to 
reduce TA in MCF7 by more than 50% and a minimum dosage of 2.5x IC50 was 
required. (n = 2) 




































































































3.2.2. Verification for EGFR inhibitors 
 
Inhibitor B (inhibitor of EGFR receptor), C (ET-18-OCH3; phosphatidylinositol-
specific phospholipase C inhibitor), G (AKT inhibitor VIII) and M (LY 294002: 
PI 3-kinase inhibitor) at a dose of 5x IC50 from the EGFR pathway inhibitor 
library were used to treat MCF7. As shown in figure 3.9, inhibitor B, C and G 
could reduce TA by about 40%.  
 
Inhibitor G that inhibits AKT was the most potent TA inhibitor in HCT116 
(Figure 3.4A) and MCF7 (Figure 3.9A). However, it was not further studied, as 
AKT is a known regulator of TA. Inhibitor B that inhibits EGFR will not be 
further pursuit as EGFR is the most upstream protein in the EGFR signaling 
pathway, therefore inhibition of EGFR will not be solely inhibiting TA and is 
expected to lead to many undesirable side effects. Therefore in the EGFR 
inhibitor library screen, only one potential novel regulator of TA was identified 






















Figure 3.9. Effect of TA by (A) EGFR pathway inhibitor B, C, G and M on  
MCF7 at a dose of 5x IC50. (B) inhibitor C (ET18-OCH3) at 5x IC50 on AGS. (n = 
2) 












































































3.3. Mechanistic study of β-catenin/TCF on hTERT  
 
The reduction of TA by β-catenin/TCF inhibitor is cell line independent as it 
reduced TA in all three major types of cancer cell lines (HCT116, LST174T, 
MCF7, and AGS) in the screening and verification experiments (Figure 3.2 to 3.5 
and Figure 3.7 to 3.8). The mechanism on how β-catenin/TCF regulates TA was 
studied in this project. β-catenin/TCF is a well-known transcriptional factor, 
therefore was expected to be regulating TA at the transcriptional level. Thus the 
effect of FH535 (β-catenin/TCF inhibitor) on mRNA expression of essential 
components of telomerase (hTERT, hTER and DKC1) was investigated. 
 
3.3.1. Effect of FH535 (β-catenin/TCF inhibitor) on mRNA expression of 
essential components of telomerase (hTERT, hTER and DKC1) and c-Myc 
 
The effects of FH535 (β-catenin/TCF inhibitor) on the mRNA expression of 
essential components of telomerase (hTERT, hTER and DKC1) were investigated 
to provide preliminary evidence that β-catenin/TCF is regulating TA at the 
transcriptional level. c-Myc was included as a positive control as it is known to be 
regulated transcriptionally by β-catenin/TCF in colon cancer cell (Akiyama 2000).  
In MCF7, FH535 reduced hTERT mRNA and has no effect on hTER mRNA. It 
up-regulated c-Myc and DKC1 mRNA (Figure 3.10A). In HCT116, FH535 




(Figure 3.10B). In both cell lines, FH535 consistently reduced hTERT mRNA 
level suggesting that β-catenin/TCF is involved in the regulation of hTERT gene 
transcription in cancer cells (Figure 3.10). In both cell lines, FH535 up-regulated 
DKC1 mRNA while the effect of the inhibitors for c-Myc and hTER is cell line 
dependent. 
The reduction of hTERT mRNA on both cell lines is consistent with the effect of 
FH535 on TA in both cell lines. Implying that the reduction of TA observed in the 
















Figure 3.10. Effect of FH535 at 2.5x IC50 on mRNA expression of core 








3.3.2. Co-relation of TA and β-catenin expression in SW480 and SW620 
 
To provide evidence that β-catenin could regulate TA in human cancer, co-
relation between β-catenin level and TA in human colon carcinoma-derived cell 
lines SW480 and SW620 were examined. The genetic back ground of the two cell 
lines were similar as SW480 cells were isolated from the primary tumor and 
SW620 was from a lymph node metastasis from the same patient a year apart. 
Though not statistically significant, qTRAP and western results showed that 
SW620 cells have 10% higher TA with a 20% increase in β-catenin expression 
level compared to SW480 cells (Figure 3.11), suggesting that β-catenin level has 

























Figure 3.11. (A) TA and (B) β-catenin protein levels in SW480 and SW620 cell 
lines. SW620 cells have 10% higher TA with a 20% increase in β-catenin 



















3.3.3. Canonical Wnt/β-catenin signaling regulates TA in cancer cell via 
hTERT transcription regulation 
 
β-catenin/TCF complex was identified as a novel telomerase activity regulator in 
the inhibitor library screen and β-catenin/TCF complex inhibitor; FH535 reduced 
the mRNA level of hTERT in cancer cell lines. In addition, there was a positive 
co-relationship between the TA and β-catenin protein level in the colon 
carcinoma-derived cell lines SW480 and SW620 (Figure 3.11). 
Taken together, the data suggest that β-catenin/TCF complex may be a positive 
regulator of TA via activating the transcription of hTERT. Implying that, hTERT 
transcription may be regulated by the canonical Wnt signaling pathway. 
The canonical Wnt signaling pathway can be activated by Wnt-3a ligand or LiCl 
treatment. Wnt-3a is a soluble ligand of the canonical Wnt pathway while LiCl 
activate Wnt signaling by inhibiting GSK-3β, both treatments will increase and 










3.3.3.1. Effect of Wnt-3a treatment on TA and mRNA level of essential 
components of telomerase (hTERT, hTER and DKC1). 
 
To provide evidence that telomerase activity (TA) is regulated by Wnt pathway 
through hTERT transcription, MCF7, HCT116, and 239T cells were treated with 
Wnt-3a conditioned medium (Wnt-3a) or control medium (CM) for 48hr. TA and 
hTERT gene transcription were measured by qTRAP and qPCR respectively. 
Compared to controls, Wnt3a treatment increased TA by about 50%, 40% and 35% 
in MCF7, HCT116 and 293T cell lines respectively (Figure 3.12). Consistent with 
this result, Wnt-3a treatment unregulated hTERT mRNA level by about 50%, 40% 
and 70% in MCF7, HCT116 and 293T cell lines (Fig. 3.13). Apart from hTERT, 
hTER and DKC1 mRNA were also elevated upon Wnt-3a treatment. Taken 
together, the data imply that activated Wnt pathway was able to stimulate hTERT 








Figure 3.12. Wnt3a treatment increased TA in MCF7, HCT116 and 293T (n = 3; 


















Figure 3.13. Effect of Wnt3a on hTERT, hTER and DKC1 mRNA level in (A) 











To provide evidence that canonical Wnt pathway positively regulate TA through 
hTERT transcription via β-catenin, the effects of LiCl on TA and hTERT mRNA 
level were studied. LiCl is a small molecular activator of the Wnt signaling 
pathway that works by inhibiting GSK-3β, resulting in the increase and 
stabilization of β-catenin protein level in cell (Stambolic et al. 1996). As shown in 
figure 3.15, 15mM of LiCl treatment for 48hr significantly elevated TA (n = 3; P 
< 0.05, t-test) in MCF7, HCT116 and 293T cell lines. In 293T, hTERT mRNA 
level was significantly (n = 3; P < 0.05, t-test) elevated after LiCl treatment but no 
significant changes in the hTER and DKC1 mRNA level occured. As the two 
genes are not the focus of the project, the effects of LiCl on the two genes were 
not studied in MCF7, HCT116, BJ and MDCF10A. hTERT mRNA level was 
significantly (n = 3; P < 0.05, t-test) increased in MCF7 and HCT116 after LiCl 
treatment, HCT116 in particular had a 5 fold increase in hTERT mRNA level. 
Thought not statically significant, LiCl treatment also increased hTERT mRNA 
level in BJ and MCF10A. Implying β-catenin plays a role in regulating hTERT 
mRNA level in both cancer cell lines and non-cancerous stable cell lines. 
 
The current data supports the functional role of β-catenin in hTERT transcription 
regulation and TA regulation in diverse cancer cell lines. In addition, the ability of 
LiCl to up-regulate hTERT transcription was not restricted to cancer cell lines but 




fibroblast cell) and MCF10A (non-cancerous mammalian breast cell line) as 


















Figure 3.14. 15mM of LiCl treatment increased TA in MCF7, HCT116 and 293T 



















Figure 3.15.  Effect of 15mM of LiCl on (A) hTERT , hTERT and DKC1 mRNA 
level in 293T, (B) hTERT mRNA on MCF7,  HCT116,  BJ and MCF10A. (n = 3; 







3.3.3.3. Effect of Wnt-3a and lithium chloride treatment on hTERT promoter 
activity in luciferase reporter assay 
 
To show that the conical Wnt pathway is indeed regulating hTERT at the 
transcriptional level, the effect of Wnt-3a and lithium chloride treatment on 
hTERT promoter luciferase activity was studied. 
 
A luciferase reporter construct 949bp hTERT consist of promoter sequence of 
hTERT from -949bp to +1, contains the proximal promoter, was shown to be 
essential for cancer specific transcription activation (Horikawa et al. 2002; Satoru 
et al. 2008).  949bp hTERT was transiently transfected into MCF7, HCT116, and 
293T cells and the cells were subjected to Wnt-3a  (Figure 3.16A) or LiCl (Figure 
3.16B) treatment. As shown in figure 3.16, both Wnt-3a and LiCl treatment could 
up-regulate the luciferase activity of 949bp hTERT in all the three cell lines 















Figure 3.16 Effect of (A) Wnt-3a and (B) 15mM LiCl treatment on 949bp hTERT 











3.3.3.4. Effect of  knocking down of β-catenin on TA, hTERT mRNA and 
949bp hTERT in cancer cell lines  
 
 
To provide further evidence that β-catenin was involved in telomerase regulation 
and was through activation of hTERT gene. β-catenin knockdown stable cell lines 
were generated from 293T, HCT116, MCF7 and MCF10A cell lines with 
lentiviral shRNA against β-catenin.  
 
The effect of β-catenin knockdown on hTERT mRNA, TA and 949bp hTERT 
promoter activity was studied and compared against scramble shRNA control. 
The β-catenin protein levels in all the four stable cell lines were significantly 
decreased as shown in figure 3.17. The efficiency of the knock down in the four 
cell lines various with HCT116 and MCF7 being the most efficient followed by 
MCF10A and 293T. Despite the different, they all had a lower level of 
intracellular β-catenin compare to their respective controls. 
 
The effects of β-catenin on hTERT mRNA level (Figure 3.18A), TA (Figure 
3.18B) and 949bp hTERT promoter activity (Figure 3.18C) were studied. Data 
showed that hTERT mRNA level, TA and 949bp hTERT promoter activity were 
reduced in all the stable cell lines with β-catenin knockdown.  
 
β-catenin knockdown reduced hTERT mRNA level in all four cell lines (Figure 
3.18A), the reduction in hTERT mRNA level was statistically significantly in 




more significant drop in the β-catenin level in these stable cell lines compared to 
293T. Though the reduction of hTERT mRNA varied in all the cell lines but it was 
enough to cause a signification reduction in TA (Figure 3.18B; n = 3; *P < 0.05, t-
test).   
 
Luciferase promoter assay was used to study the effect of β-catenin knockdown 
on 949bp hTERT promoter activity (Figure 3.18C) in MCF7, HCT116 and 293T. 
Consistent with the drop in hTERT mRNA, the knock down also reduced the 





















Figure 3.17.  Western blots showing β-catenin (upper panel) and actin (lower 






































Figure 3.18.  Effect of β-catenin knockdown on (A) hTERT mRNA and (B) TA in MCF7, 
HCT116, 293T and MCF10A. (C) Effect of β-catenin knockdown on 949bp hTERT 







3.3.3.5. Effect of  knocking down of β-catenin on telomere length in cancer 
cell lines  
 
 
hTERT is known to be required for the maintenance of telomere length in cancer 
cells. Therefore the effect of knocking down β-catenin on telomere length in cells 
was studied by comparing the telomere length of cells with stable β-catenin 
knockdown to their respective controls stable cell line transfected with scramble 
shRNA lentivirus. 
The stable cancer cell lines were cultured over 90 days through 30 cell passages. 
Cells were collected on day 1 and day 90, the effect of β-catenin knockdown on 
telomere length was determined by southern blotting. Telomere signals appeared 
as a broad smear of densities and the average length of the telomere in the pool of 
cells were determined for comparism. As shown in figure 3.19 (comparing lane 1 
and 3 in each type of cancer cell lines) after 90 days of culturing there was no 
difference in the density of the smear in the controls and there was no change in 
the average length of the telomere in the controls (table 3.3). In the β-catenin 
knockdown cell lines (comparing lane 2 and 4 in each type of cancer cell lines in 
Figure 3.19), there were reductions of density in the smear and the average length 
of the telomere reduced from 2.5 to 2.0Kb in HCT116, 2.7 to 2.3Kb in MCF7 and 
3.0 to 2.6Kb in MCF10A after 90 days of culture (table 3.3). These implied that 
β-catenin knockdown led to telomere shortening in HCT116, MCF7 and 
MCF10A cells compared to the respective controls. However, the silencing of β-




3.20 and table 3.3). It is possible that β-catenin knockdown may take a longer 










Figure 3.19. β-catenin knockdown caused telomere shortening in HCT116, MCF7 
and MCF10A cells.  
21.2 





Figure 3.20. β-catenin knockdown in 293T cell lines does not affect the mean 
















Cell Lines Mean telomere length 
on Day 1/Kbs 
Mean telomere length 
on Day 90/Kbs 
HCT116 (Scramble) 2.2 2.2 
HCT116 (β-catenin RNA) 2.2 2.0 
MCF7 (Scramble) 2.7 2.7 
MCF7 (β-catenin RNA) 2.7 2.3 
MCF10A (Scramble) 3.0 3.0 
MCF10A (β-catenin RNA) 3.0 2.6 
293T (Scramble) 2.7 2.7 
293T (β-catenin RNA) 2.7 2.7 
 
Table 3.3 The mean telomere length of HCT116, MCF7, MCF10A and 293T cell 
lines with scramble shRNA or β-catenin RNA lentivirus treatment on day 1 and 



































3.3.4. Effect of over expression of β-catenin on TA, hTERT mRNA and 949bp 




The effect of over expression of β-catenin on TA, hTERT mRNA and 949bp 
hTERT promoter activity was studied to provide another line of evidence that 
hTERT is regulated in a β-catenin-dependent manner. A constitutively active form 
of β-catenin (Δ-N β-catenin) was transiently expressed in 293T, HCT116, and 
MCF7 cells. The effect of high level of consistuitive active β-catenin on hTERT 
mRNA expression, TA and 949bp hTERT promoter activity was studied using 
qPCR, qTRAP and luciferase promoter assay respectively. As shown in figure 
3.21, transient expression of Δ-N β-catenin up-regulated transcription of the 
hTERT, elevated TA and increased 949bp hTERT promoter activity.  
In addition, stable cell lines over expressing β-catenin were generated using 
retroviral expression system to study the effect of long term over expression of 
wild type β-catenin on hTERT mRNA expression, TA and telomere length. As 
shown in figure 3.22, the hTERT mRNA level in the stable cell lines over 
expressing β-catenin in MCF7, HCT116 and 293T were increased by more than 
50% compare to their respective controls. TA was also increased in all the three 
cell lines with MCF7 and HCT116 being statistically significant (n = 3; *P < 0.05, 
t-test).  Though both hTERT mRNA expression and TA were significantly 
elevated in HCT116 stable cell lines with β-catenin over expression stable cell 
lines as compared to control, there was no difference between the mean telomere 
lengths in both cell lines after 90 days of cultivation. This may imply that β-




Alternatively, immortalized cell may activate telomerase to maintain telomere 





























Figure 3.21.  Effect of Δ-N β-catenin transient over expression on (A) TA, (B) 
hTERT mRNA (C) hTERT (949bp) promoter activity in MCF7, HCT116 and 
293T cell lines. (n = 3; ± S.D. *P < 0.05, t-test). 
 
Effect of Δ-N Beta-catenin on 














































































Figure 3.22 Effect of β-catenin over expression on (A) TA, (B) hTERT mRNA in 
MCF7, HCT116 and 293T β-catenin-expression stable cell line. (n = 3; ± S.D. *P 










Cell lines Mean telomere length on Day 
90/Kbs 
HCT116 (Control) 2.2 















The inhibitor FH535 disrupts β-catenin mediated transcription through inhibiting 
the interaction between β-catenin and TCF. The next step taken in the project is to 
show the involvement of TCF in hTERT transactivation and to identify the exact 
TCF member that β-catenin interacts with to activate hTERT transcription.   
 
3.3.5.1. TCF is involved in β-catenin dependent transcription of hTERT in 
cancer cell lines 
 
The TAK1-NLK (Transforming growth factor-β-activated kinase 1 and Nemo-
like kinase) pathway is a negative regulator of the canonical Wnt/β-catenin 
signaling pathway. When activated, TAK1 and TAB1 (TAK1 binding protein) 
form an active complex that will in turn activate NLK. NLK will then 
phosphorylate LEF/TCFs to prevent the β-catenin-LEF/TCFs complex from 
binding to DNA (Ishitani et al. 1999; Yamada et al., 2006). 
 
The transactivation of the hTERT (949bp) promoter by endogenous β-
catenin/TCF complexes was strongly repressed by co-transfection of TAK1 and 
TAB1 compared to the control which were transfected with the with the empty 
vector pCDNA3 (Fig. 3.23) in luciferase reporter assay.  The decrease in 























Figure 3.23. Effect of endogenous β-catenin/TCF complexes inhibition by 













3.3.5.2. β-catenin/TCF4  regulate hTERT promoter in cancer cell lines 
 
When the Wnt path way is activated, β-catenin will translocate to the nucleus and 
form hetero-dimer with members of the TCF. The dimer will activate Wnt target 
(Yokoyama et al. 2006). In higher organisms, there are four members in the 
family namely LEF-1, TCF-1, TCF-3 and TCF-4.  
 
The effect of coexpression of Δ-N β-catenin (constitutional active form of β-
catenin) with different LEF/TCFs members on hTERT (949bp) luciferase 
promoter was studied in 293T, HCT116, and MCF7 cells. All the cells were 
transfected with hTERT (949bp) promoter and either transfected with pCDNA 
(control vector), Δ-N β-catenin or Δ-N β-catenin with a different TCF/LEF (LEF-
1, TCF-1, TCF-3 or TCF-4). As shown in figure 3.24, over expression of Δ-N β-
catenin alone could slightly increase hTERT (949bp) promoter activity; the 
promoter activity was further increase in co-transfection of Δ-N β-catenin and 
TCF4. Comparing against pCDNA, the promoter activity was significantly (n = 3; 
*P < 0.05, t-test) increased by 2 fold in MCF7, 1 fold in HCT116 and 0.5 fold in 
293T when the cell lines were co-transfection of Δ-N β-catenin and TCF4. β-
catenin/TCF1/3 or LEF1 complexes caused a slight increase in promoter activity 
in MCF7 and HCT116 but a decrease in 293T. In addition, the elevation of 
hTERT (949bp) promoter activity by co-expression of Δ-N β-catenin and TCF4 
was significantly reduced (n = 3; *P < 0.05, t-test) in the presence of 








Figure 3.24. Co-expression of β-catenin and TCF4 could significantly elevated 
luciferase activity  of  the 949bp hTERT promoter in MCF7, HCT116 and 293T. 














Figure 3.25. Overexpressing TAK1/TAB in MCF7, HCT116 and 293T cell lines 
(β-catenin and TCF4 over expression cell line) significantly reduced hTERT  













Co-expression of Δ-N β-catenin and TCF4 could also significantly elevate (n = 3; 
*P < 0.05, t-test) hTERT mRNA and TA in MCF7, HCT116 and 293T. hTERT 
mRNA was increased by 30% in MCF7, 60% in HCT116 and 40% in 293T. The 
increase of hTERT mRNA was consistent, thought not directly proportional with, 
the increase in TA in the cell lines.  TA was increased by 100% in MCF7, 50% in 
HCT116 and 70% in 293T.  
 
Taken together, the data implied that β-catenin form a transcriptional complex 



















Figure 3.26. Co-expression of β-catenin and TCF4 could significantly elevated 
(A) TA and (B) hTERT mRNA (C) hTETR (949bp) promoter activity in MCF7, 








3.3.5.3. Characterization of the distal TCF4 binding site (TBE) in the human 
hTERT promoter 
 
The approximate location of the β-catenin/TCF4 binding site of the complex was 
determined by transfecting of β-catenin/TCF4 with wild type hTERT promoters of 
different length (88, 385, and 949 bp; Figure 3.27) into MCF7, HCT116 and 293T. 
As shown in figure 3.27, 949 bp promoters could induce a significantly higher 
luciferase activity compared to the 88bp and 385 bp promoter in the presence of 
β-catenin/TCF4. (n = 3; *P < 0.05, t-test). The up-regulated promoter activity of 
the 949 bp hTERT promoter was significantly reduced (n = 3; *P < 0.05, t-test) in 
the presence of TAK1 and TAB (Fig. 3.28). Taken together, this implied that β-
catenin/TCF4 regulates hTERT transcriptionally at a distal TCF4 binding site/s 










Figure 3.27. Effect of β-catenin/TCF4 over expression on wild type hTERT 
promoters of different length (88, 385, and 949 bp) in MCF7, HCT116 and 293T 























Figure 3.28. Overexpressing TAK1/TAB/ β-catenin/TCF4 in (A) MCF7, (B) 
HCT116 and (C) 293T cell lines significantly reduced hTERT  (949bp) promoter 














Indeed, when the genomic DNA of hTERT (obtained from Cold spring data base 
hchr5 00954) was analyzed using TESS (Transcription Element Search System), a 
putative consensus TCF binding element (TBE) between position -659bp and -
653bp (5’-TGCAAAG-3’) upstream of transcription start site of hTERT was 
discovered (Figure 3.29).  The putative site has a high degree of homology to the 
core consensus sequence (CTTTG or CAAAG) (Alexander-Bridges et al. 1992). 
 
Mutation and deletion studies were carried out to prove that the putative TCF4 
binding site is essential for the promoter activity of hTERT. Three mutants (M1, 
M2 and M3) with mutations in the TBE and a wild type hTERT (652bp) promoter 
without the TBE site were generated. The TBE sequence of the hTERT promoter 
is: 5’-TGCAAAG-3’, substitution mutation was introduced in M1, M2 and M3 in 
the TBE site. The first adenine from the 5’ end was replaced by guanine in M1 
(5’-TGCGAAG-3’), the first and second adenine from the 5’ end was replaced by 
guanine in M2 (5’-TGCGGAG-3’) and in M3 adenine to guanine and guanine to 
adenine substitution was constructed at the last two nucleotide of TBE site. (5’-
TGCAAGA-3’).  
As shown in figure 3.30, mutations of the TBE site reduced the stimulatory effect 
of β-catenin/TCF4 in MCF7, HCT116 and 293T, while the deletion of the TBE 
significantly repressed the hTERT promoter activity in all the three cell lines. (n = 
3; *P < 0.05, t-test). In MCF7 and 293T, a single nucleotide replacement of 




the activity was further reduced when two adenine from the 5’ end was replaced 
by guanine in M2 (5’-TGCGGAG-3’), showing a dosage dependent decrease of 
the mutation. The reduction of promoter activity was most drastic when the TBE 
site was absent with hTERT (652bp) promoter having the least promoter activity 














































Figure 3.30. Effect of  mutation of  TBE on 949bp hTERT promoter luciferase 








3.3.5.4. In vitro and in vivo occupancy of TCF4 on TBE in hTERT promoter  
 
In vitro occupancy of TCF4 on TBE of hTERT promoter was shown using 
electrophoretic mobility shift assays (EMSA). As shown in Figure 2.31A lane 3, 
cell lysate of 293T cells over expressing β-catenin/TCF4 could bind to the wild-
type (WT) TBE probes while mutant M2 TBE probes could not form any 
complex with β-catenin/TCF4 (Figure 2.31A lane 6). In the competition assay, 
unlabeled WT TBE oligonucleotide in 500X excess could effectively inhibit 
complex formation between β-catenin/TCF4 and labeled WT probe (Figure 2.31A 
lane 4) whereas unlabeled mutant oligonucleotides M2 failed to do so (Figure 
2.31A lane 5).  In the presence of TCF4 antibodies (Figure 2.31B lane 4), a 
supershift was formed implying that the TCF4 was part of the protein complex 
that bounded to the labeled WT probe. Both normal IgG and anti c-Myc 
















M2 : ctgagaacctgcggagagaaatgac 
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Figure 3.31 Sequence specific interaction between β-catenin/TCF4 and TBE on 
hTERT promoter. (A) EMSA using TBE containing probe with cell lysate of 293T 
cells and cell lysate of 293T cells over expressing β-catenin/TCF4 was used. 
Oligonucleotide probes containing wild-type or M2 TBE site in the absence or 
presence of a 500-fold molar excess of non-labeled oligonucleotides that 
contained either wild-type or M2 TBE site was added to the two types of lysate. 
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In vivo occupancy of TCF4 on the hTERT promoter was shown using TCF4 
specific antibody in chromatin immunoprecipitation (ChIP) and quantified using 
qPCR. Four sets of primers were used in the experiments: two set of primers 
(hTERT1 and hTERT2) that amplified the TBE site on hTERT promoter, SP5 
primers amplifying the SP5 promoter (which is a well-known Wnt/β- 
catenin/TCF4 target gene) was used as a positive control and GAPDH primers 
amplifying a region in the glyceraldehydes-3-phosphate dehydrogenase (GAPDH) 
coding region as a negative control.  
Figure 3.32A shows the occupancy of TCF4 on hTERT promoter, as there are 
more than 3 fold enrichment of signals in TCF4 pull down compare to IgG for 
both hTERT1 and hTERT2. The TCF4 pull down was specific as there was no 
signal from the negative control GAPDH primers and the hTERT primers produce 
similar signal (hTETR1) if not higher (hTERT2) as compared to positive control 









Figure 3.32. CHIP assay showing (A) the occupany of TCF4 in hTERT promoter 














This project shows that hTERT (human telomerase reverse transcriptase) is a 
novel transcriptional target of the canonical Wnt pathway and is regulated by β-
catenin/TCF4 complex.  
 
Telomerase activation is responsible for one of the important hallmarks of cancer, 
which is the infinite proliferative capacity in diverse types of cancer (Harley et al. 
1994; Takakura et al. 1998; Kyo et al. 1999; Hanahan and Weinberg 2000). In 
addition, telomerase activity is universally present in human cancers and almost 
absent in most normal tissues therefore its an attractive therapeutic target. Studies 
have also shown that though telomerase is a multi components protein complex, 
only hTERT expression is highly specific to cancer cells and tightly associated 
with telomerase activity (Kanaya et al. 1998; Takakura et al. 1998; Kyo et al. 
1999). The expression of hTERT is regulated at multiple levels but is primarily 
regulated at the transcription level (Ulaner et al. 1998). 
 
Despite tremendous effect in defining telomerase regulation in cancer cells, it 
remains unclear how cancer cells reactivate telomerase. A possible way for 
tumor-specific activation of telomerase could be through the activation of the 
hTERT promoter via tumor-specific cellular factors. Many oncogenes identified to 
date are transcription factors or co-factors; a well-known example is β-catenin 




major role in the progression of many types of cancer (Polakis 2000). Park et al. 
(2009) had shown that hTERT plays an essential role in Wnt/β-catenin signaling 
pathway by serving as a cofactor in a β-catenin transcriptional complex. However, 
the role of Wnt/β-catenin signaling pathway in telomerase regulation was not 
investigated. 
 
When screening the InhibitorSelect™ inhibitor library (consisting of Wnt, EGFR 
and JAK/STAT inhibitor library) in a real-time PCR based TRAP assay, FH535 
(a known specfic inhibitor of β-catenin/TCF complex inhibitor) was found to be a 
very promising hit.   It could effectively inhibit telomerase activity (TA) in gastric 
cancer, breast cancer, and colorectal cancer cell lines. In addition, FH535 
treatment caused a significant decrease in hTERT mRNA level in HCT116 and 
MCF7 cells (Figure 3.10), implying that β-catenin/TCF complex is involved in 
the transcription regulation of hTERT. This leads to the hypothesis that Wnt/β-
catenin pathway may have a role regulation TA through hTERT transcription. 
 
The first line of evidence that TA was regulated by Wnt pathway through hTERT 
transcription via β-catenin came from Wnt-3a and LiCl studies. Treatment of 
MCF7, HCT116, and 239T cells with either Wnt-3a conditioned medium or LiCl 
lead to a significant increase of TA (Figure 3.12 and Figure 3.14), hTERT mRNA 
level (Figure 3.13 and Figure 3.15) and hTERT (949bp) promoter activity (Figure 
3.16) in MCF7, HCT116 and 293T cell lines. In line with the data, stable cell 




level (Figure 3.18B) and hTERT (949bp) promoter activity (Figure 3.18C). In 
addition, β-catenin knock down also caused shortening of telomere length in these 
cell lines. On the other hand, both cell lines with transient expression of activated 
form of β-catenin (Δ-N β-catenin) or stable cell lines over expression β-catenin 
could up regulate TA (Fig. 3.21A and Fig. 3.22A), hTERT mRNA level (Figure 
3.21B and Figure 3.22B) and hTERT (949bp) promoter activity (Fig. 3.21C). In 
addition, the activation of Wnt pathway could increase hTERT gene expression 
and reactivate telomerase in human normal fibroblast cells leading to an extended 
life span in these cells (Zhang et al. 2012). Taken together, this show that 
activation of telomerase via the Wnt pathway can induce cell growth via the 
activation of telomerase. 
 
When the canonical Wnt pathway is activated, β-catenin degradation will be 
inhibited and it will accumulate and translocate to the nucleus. As β-catenin only 
has transcriptional activating domain and lacks DNA binding domain, it often 
form transcriptional complex with members of the LEF/TCF family of proteins in 
order to initiate transcription of Wnt target genes (Barker et al. 2000). TAK1-
NLK (Transforming growth factor-β-activated kinase 1 and Nemo-like kinase) 
pathway is a negative regulator of the canonical Wnt/β-catenin signaling pathway. 
When activated, TAK1 and TAB1 (TAK1 binding protein) formed an active 
complex that will in turn activate NLK. NLK will then phosphorylate LEF/TCF to 
prevent the β-catenin-LEF/TCF complex from binding to DNA (Yamada et al. 




catenin/TCF complexes was strongly repressed by co-transfection of TAK1 and 
TAB1 (Figure 3.23) in luciferase reporter assay.  
 
In higher organisms, there are four members in the LEF/TCF family namely 
LEF1, TCF1, TCF3 and TCF4. All of them bind DNA through their high-mobility 
group (HMG) domain which recognizes the consensus sequence CTTTGWW 
(W=A or T) (Oosterwegel et al. 1991; Travis, Amsterdam et al. 1991; Waterman 
et al. 1991; Brantjes et al. 2002). Members of the LEF/TCF family share up to 95% 
amino-acid sequence conservation in HMG domain and bind to the same 
consensus sequence, but play diverse roles in cell growth, development, and 
differentiation due to epigenetic mechanisms and selective promoter occupancy  
(Yokoyama et al. 2006; Wöhrle et al. 2007) 
 
In the context of hTERT promoter, β-catenin forms a transcription complex with 
TCF4 in transcription activation. As shown in figure 3.24, Δ-N β-catenin /TCF4 is 
the most effective transcription activator of hTERT (949bp) promoter in luciferase 
assay in MCF7, HCT116 and 293T cell lines. Over expression of both Δ-N β-
catenin and TCF4 in these cells also lead to significant increase of TA and hTERT 
mRNA level Figure 3.26.  
 
When the genomic DNA of hTERT was analyzed using TESS (Transcription 
Element Search System), a putative consensus TCF binding element (TBE) 




transcription start site of hTERT was discovered (Figure 3.29).  The putative site 
has a high degree of homology to the core consensus sequence (CTTTG or 
CAAAG) (Alexander-Bridges et al. 1992). In addition, the location of the TBE 
site on hTERT promoter is beyond the proximal promoter (Figure 3.29), which is 
consistent with most TBS sites in other genes (Hatzis et al. 2008). The TBE site in 
hTERT promoter is functional and essential for β-catenin/TCF4 mediated 
transcriptional activation in luciferase assay. Mutations of the TBE reduced the 
promoter activity while deletion almost eliminated the promoter activity (Figure 
3.30). Finally, EMSA (Figure 2.31) and ChIP (Figure 2.32) showed the in vitro 
and in vivo occupancy of TCF4 on the TBE of hTERT promoter.  
 
This project has shown that hTERT is the novel gene target of the Wnt pathway 
and TBE is essential for the transcription regulation of hTERT in cancer cells. 
Wnt/β-catenin signaling pathway regulates telomerase through the transcriptional 
regulation of hTERT.  In conclusion, this study shows the biological roles of 
Wnt/β-catenin signaling pathway in regulating telomerase acitivy in major types 
of human cancers. High telomerase acitivy is common in human cancers and 
understanding the role of β-catenin/TCF4 complex in telomerase regulation is of 
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